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ABSTRACT
SEIZURE AND BEHAVIORAL PHENOTYPING OF THE SCN1A MOUSE MODEL
OF GENETIC EPILEPSY WITH FEBRILE SEIZURES PLUS
by
ASHLEY W. HELVIG
Genetic epilepsy with febrile seizures plus (GEFS+) is associated with a wide
range of neurological dysfunction caused in part by limited function in voltage-gated
sodium channels (Escayg & Goldin, 2010; Gambardella & Marini, 2009; Mulley et al.,
2005). The seizure and behavioral phenotypes, as well as use of non-pharmacologic
agents as neuroprotectants in GEFS+, are not well-understood. An experimental design
used an animal model of GEFS+ to 1. explore the effects of stress on seizure phenotype,
2. examine behavioral phenotypes, and 3. study the effects of an omega 3 fatty acid on
abnormal behaviors noted in the various paradigms.
This study used C57BL/6J mice with the R1648H missense mutation on the
Scn1a gene (engineered in the Escayg lab) (Martin, M. S. et al., 2010). The three specific
aims used separate groups of animals for experimentation, and all paradigms were
performed under strict laboratory conditions.
Data were analyzed using either an independent t-tests, two-way ANOVA or
repeated measures two-way ANOVA. Results showed that stress worsens seizure
iv

phenotype in both the Scn1aR1648H (RH) mutants and wild-type (WT) group with the RH
mutants more severely impacted. In addition, there was clear and consistent evidence for
hyperactive locomotor behavior. Lastly, no evidence was found for use of
docosahexaenoic acid (DHA, an omega 3 fatty acid) as a neuroprotectant for
hyperactivity (DHA was given subcutaneously for two weeks starting at weaning).
Outcomes from this study implicate that stress worsens the seizure phenotype in
animals with Scn1aR1648H. This study is also the first to report hyperactive locomotor
behavior in animals with Scn1aR1648H. Results from this study may broaden beyond
GEFS+ in that we may also be able to apply the findings to other disorders with SCN1A
dysfunction. In addition, it may be that genetic variants affecting SCN1A, but not
necessarily in epilepsy, may contribute to hyperactivity. This could mean that SCN1A is
a candidate gene for hyperactivity. The main goal of nursing care is to reduce and
prevent disease morbidity, and knowledge gained from the current study will guide
clinical nursing practice, such as targeted behavioral assessment and education, as well as
nursing research focusing on children with this genetic disorder.
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CHAPTER I
INTRODUCTION
Chapter one consists of the overall significance of the problem of epilepsy,
specifically genetic epilepsy with febrile seizures plus (GEFS+), the impact of stress on
seizure activity as well as behavior (i.e., anxiety, depression or social stress), and
explores omega 3 polyunsaturated fatty acids (PUFA’s) as a neuroprotectant against
undesirable neurological outcomes. Descriptions of the specific aims and hypotheses are
also presented. Lastly, an explanation of the physiological theory of stress and epilepsy
that was used to guide this study is given. We hypothesized that stress will negatively
impact seizure and behavioral phenotypes, and that consumption of omega 3
polyunsaturated fatty acids will provide neuroprotection against neurological deficits.
This study uses an animal model consisting of mice with the R1648H (RH) missense
mutation on the Scn1a gene which recapitulates the human condition of GEFS+ (Martin,
M. S. et al., 2010).
Significance of the Problem
Epilepsy
Epilepsy is described as a wide spectrum of disorders that involves seizure
activity (http://www.epilepsyfoundation.org/). It usually manifests early in life or in later
adulthood but can begin in adolescence or middle adulthood as well. Approximately 3
1
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million people in the United States are affected by epilepsy (http://www.epilepsy
foundation.org/), and compared to the general population, these individuals have a
potential 2 to 3 times higher rate of mortality (Terra, Arida, Rabello, Cavalheiro, &
Scorza, 2011). Even though 60% of cases are due to an injury or other disease processes,
40% of cases have an unknown origin (Escayg & Goldin, 2010). Children who have
simple febrile seizures (seizure activity initiated by a fever) usually stop having seizures
by the age of six (http://www.ninds.nih.gov/disorders/febrile_ seizures/febrile_
seizures.htm). The Epilepsy Foundation reports that children (less than age ten) are more
likely to have generalized seizures whereas partial seizures are more common after age
ten.
Abnormal electrical activity in the central nervous system initiates the seizure
activity and can produce a wide range of neurological activity from absence seizures to
generalized tonic-clonic seizures (http://www.epilepsyfoundation.org/). Absence
seizures are considered to be benign, although they can affect learning and memory, and
are characterized by staring. Myoclonic seizure activity consists of sudden jerks of
muscles, typically bilaterally. Partial seizures occur when only a specific area of the
brain is impacted by hyperexcitability and can lead to various types of movements or
sensations depending on the location in the brain. Generalized seizures impacts both
sides of the brain and can lead to generalized tonic-clonic seizures that consist of
stiffening of muscles and then jerking movements of the extremities and face. Febrile
seizures can produce tonic-clonic seizures and can be frightening to parents; however,
these are usually benign and do not persist past age six (http://www.epilepsy
foundation.org/). Certain epileptic disorders can be extremely severe such as Dravet
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syndrome. This is a disorder that occurs in the first months of life and causes
developmental delay, mental retardation, ataxia, and decreased life expectancy (Escayg &
Goldin, 2010).
In addition to physiological effects, many psychological effects have been linked
with seizure disorders. Depression has been found in a large number of people with
epilepsy (de Souza & Salgado, 2006; Ottman et al., 2011). Many people with epilepsy
and co-morbid depression are taking multiple anti-epileptic medications, have limitations
set upon them such as not being able to drive, and have feelings of isolation (Lu &
Elliott, 2011). Anxiety is also a problem for persons with epilepsy (de Oliveira et al.,
2011; Ottman et al., 2011). Many times seizures are not well-controlled, thus the
unknown possibility of seizure activity is anxiety-producing. Also, the concern if a
seizure happens during work or school and the worry of how other people will react are
important factors for patients with epilepsy. Suicidal thoughts have also been associated
with people who have seizure disorders (de Oliveira et al., 2011).
Physiological and Emotional Stress
During the stress response, there are 2 basic physiological responses. One
response involves the short acting sympathetic system acting to increase epinephrine and
norepinephrine which increase heart rate, mental acuity, and blood pressure. The second
response involves the Hypothalamic-Pituitary-Adrenal (HPA) axis. The hypothalamus
secretes corticotrophin releasing factor (CRF) which stimulates the pituitary to release
adrenocorticotropic hormone (ACTH) which in turn stimulates corticosterone release
from the adrenal glands (Brunson, Avishai-Eliner, & Baram, 2002; de Kloet, Joels, &
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Holsboer, 2005). Corticosterone is responsible for the release of glucocorticoids and
mineralocorticoids. The stressful event is subjective, and the appraisal center of the brain
consists of the limbic system. It is important to remember that stress can be a
physiological stressor such as a wound infection or seizure, or it can be a psychological
stressor which is interpreted individually.
Stress and Epilepsy
Multiple studies have attempted to examine the correlation between stress and
epilepsy. However it is difficult to study stress in epilepsy because it is multi-factoral
(Lai & Trimble, 1997; Swinkels et al., 1998). For example, it is difficult to quantify
stress, and stress itself can lead to other issues such as depression, sleep problems or
unhealthy habits (drinking alcohol or smoking). Additionally, the seizure itself is a
stressor (Lai & Trimble, 1997).
In general, animal studies as well as human studies report that seizure activity
induces the stress response (increase in stress hormones), and stress can negatively
impact seizure activity; however, there are a few studies that report anti-convulsive
properties of stress (Abel & Berman, 1993; Sawyer & Escayg, 2010). Also, researchers
have examined physiological responses to stress in people with epilepsy and found
alterations in the HPA axis (Zobel et al., 2004). These findings are also validated in
animal studies (Ehlers et al., 1983; Mazarati et al., 2009).
Multiple studies have examined the prevalence of behavioral outcomes to stress
such as anxiety and depression in humans as well as in animal models of epilepsy with
varying outcomes. Lu and Elliott (2011) examined mental health in people with epilepsy
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and reported that the seizure frequency itself was not correlated with poor mental health,
but rather the activity limitations that having seizures created. These findings add to the
body of knowledge that studying stress and epilepsy in humans is complex. Animal
models of stress and epilepsy may help to provide better insight into the outcomes and
mechanisms through which stress impacts epilepsy since most variables can be
controlled.
Basically there are multiple models of stress and epilepsy that have reported
multiple outcomes (Sawyer & Escayg, 2010). Therefore it is important to examine this
particular genotype because it is a model of a human condition. No one has specifically
looked at the variables in the current study.
Epilepsy and the Co-Morbid Condition of ADHD
The association between epilepsy and ADHD has long been established with
reports of significantly higher levels of ADHD in children with epilepsy compared to
those without epilepsy (Cohen et al., 2012; McDermott, Mani, & Krishnawami, 1995;
Russ, Larson, & Halfon, 2012). Similar findings are reported in adults with epilepsy
(Ottman et al., 2011). Despite the growing body of knowledge of epilepsy and symptoms
of ADHD, there is little research regarding the specific disorder of GEFS+ and
hyperactive behavior. Case reports (Grant & Vazquez, 2005) and even larger studies
(Brunklaus, Dorris, & Zuberi, 2011) indicate a possible association of various symptoms
of ADHD in persons with GEFS+, but these are typically reported in the context of the
most severe cases of GEFS+. This is a gap in the literature that will be addressed by the
current study.
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Significance of ADHD.
Hyperactive behavior is generally characterized in the diagnosis of a combined
deficit of attention and hyperactivity as in attention-deficit hyperactivity disorder or
ADHD in humans. Attention-deficit hyperactivity disorder is increasing in incidence
(CDC, 2010), though it is not understood if this is due to the improved ability to diagnose
ADHD or if new cases are actually increasing. In the United States, approximately 8% of
children ages 3-17 were reported to have ADHD in 2008 (Bloom, Cohen, & Freeman,
2009). Poorer school performance (Diamantopoulou, Rydell, Thorell, & Bohlin, 2007),
lower IQ scores and increased enrollment in special education (van Baar, Vermaas,
Knots, de Kleine, & Soons, 2009), increased drug addiction (Falck, Wang, & Carlson,
2008) as well as higher levels of antisocial and criminal behavior (Langley, K. et al.,
2010) are associated with ADHD. More than $50 billion annually can be attributed to
costs associated with ADHD; for example, medication and medical costs, special
education, juvenile justice, and lost parent work days (Pelham, Foster, & Robb, 2007).
Attention deficit hyperactivity disorder not only impacts the cognitive and social
functioning of the child, it is a growing problem impacting society in many aspects.
Genetics and ADHD.
Although environmental factors play a role in ADHD such as maternal smoking
(Langley, Holmans, Van den Bree, & Thapar, 2007; Milberger, Biederman, Faraone,
Chen, & Jones, 1996) and maternal alcohol consumption (Knopik et al., 2005), a genetic
link to ADHD is becoming more apparent (Gilby, Thorne, Patey, & McIntyre, 2007;
Ross, 2012). As is the case with many physiological and psychological disorders, both
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genetics and environment probably work together in various ways to impact hyperactive
behavior. This animal model of a sodium channel mutation could possibly provide
insight into another genetic link to hyperactive behavior.
Treatment Modalities for Epilepsy
Treatment for epilepsy primarily consists of pharmacological agents such as
antiepileptics (i.e., 7henobarbital, phenytoin and valproic acid) or benzodiazepines (i.e.,
clonazepam and lorazepam) (http://www.epilepsyfoundation.org/; Karch, 2012);
however, some people with seizures refractory to medications use alternate treatment
methods. Approximately 50% of people with epilepsy have complete seizure control for
long periods of time, and 20% have very good seizure control with only occasional
seizures; however, 30% of people have intractable seizures (http://www.epilepsy
foundation.org/). For the 30% of patients with seizures refractory to medications, some
choose to undergo surgery to remove the seizure-producing area of the brain (mainly
performed in adults).
A dietary treatment used mainly in children is the ketogenic diet which uses
stored fat for energy (80% of the diet is fat). Some patients use vagus nerve stimulation
in which an electrode is implanted to send bursts of electrical activity via the vagus nerve
into the brain (http://www.epilepsyfoundation.org/). It is important to note that all of
these methods are treatments for epilepsy, and that there are no treatments to date that
provide neuroprotection against seizure activity (prevention of seizure activity occurring
in the first place).
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Omega 3 PUFA’s and the Brain
Omega 3 PUFA’s are essential fatty acids meaning they are found everywhere in
the body, are essential in cell functioning (Holman, 1998), and because humans are not
able to synthesize omega 3 PUFA’s, the body’s supply comes from consumption
(Niemoller, Stark, & Bazan, 2009; Schuchardt, Huss, Strauss-Grabo, & Hahn, 2009).
While there are multiple n-3 fatty acids in the body, the main omega 3 fatty acids are
docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), and alpha linolenic acid
(ALA). Both DHA and EPA are mainly found in animal sources and ALA is found
mainly in non-animal sources (Taha, Burnham, & Auvin, 2010). One of the benefits of
consumption of omega 3 PUFA’s is that there rarely are side effects (Taha et al., 2010).
DHA is the only fatty acid concentrated in the brain (Bazan, 2007). In addition,
the phospholipid bilayer of neurons contains DHA most abundantly compared to other
omega 3 fatty acids (Niemoller et al., 2009). And while the phospholipid layer of
neuronal membranes are reported to have a large quantity of DHA during the postnatal
period (Bazan, Musto, & Knott, 2011), Yavin (2006) states that DHA increases during
different periods of fetal brain growth, emphasizing the importance of DHA in the
development of the CNS. The building of critical brain circuits during the pre-natal as
well as post-natal developmental period relies on the supply of DHA (Bazan, et al.,
2011). Additionally, it is understood that DHA specifically interacts with ion channels
(Taha et al., 2010).
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Purpose
The purpose of this study was to build upon animal models of genetic epilepsy
with febrile seizures plus (GEFS+) by examining the stress response in mice with the
R1648H (RH) missense mutation in the Scn1a gene as well as the ability of omega 3 fatty
acids to protect against abnormal neurological activity.
Significance of the Study
To accomplish this, we will expand upon previous research that has linked stress
and seizure activity as well as research focusing on the neuroprotective effects of omega
3 fatty acids. Epilepsy affects approximately 3 million people in the United States with
an economic impact of over $17 billion per year (http://www.epilepsyfoundation.org/).
Unlike simple febrile seizures that typically do not occur in children greater than six
years of age, individuals with GEFS+ often experience febrile seizures into their teenage
years and develop epilepsy in adulthood (Burgess, 2005). GEFS+ is an inherited disorder
with a wide variety of symptom severity and age of onset (Escayg & Goldin, 2010) and
may be associated with learning deficits, behavioral problems, neuropsychiatric disorders
and developmental delay (Mahoney et al., 2009). Hyperactive behavior has also been
reported in children with epileptic disorders (McDermott et al., 1995; Russ et al., 2012)
as well as being associated specifically with Dravet syndrome (a severe form of GEFS+)
(Brunklaus et al., 2011). In addition, physiological and emotional stress is a concern for
people with epilepsy, and human studies have reported stress increases seizure frequency
and severity (Bosnjak, Vukovic-Bobic, & Mejaski-Bosnjak, 2002; Swinkels et al., 1998).
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Multiple pharmacologic therapies are available for the treatment for epilepsy and
co-morbid conditions such as hyperactivity; however, some people continue to have
deficits that are refractory to medications or experience untoward side effects. Because
of the reduced efficacy of medications in some people, it is important to examine the
impact of non-pharmacologic therapies for neurologic deficits. Omega 3 polyunsaturated
fatty acids (PUFA’s) have been studied for many years as protection for or treatment
against various disease processes; however, its use in neurologic disorders is still being
uncovered. The lack of consistent data regarding the impact of stress in epilepsy,
specifically in GEFS+, and non-pharmacologic treatment of neurological sequelae
undermines the assessment and treatment of patients with epilepsy and emphasizes the
need to study these areas.
Animal models of human diseases provide unique opportunities to study
unexplored phenomenon. Animals used in the current study were generated by knock-in
of the human SCN1A R1648H missense mutation into the mouse Scn1a gene (Martin et
al., 2010); therefore, this model recapitulates the human condition of GEFS+.
Additionally, the mouse strain C57BL/6J is a good animal for behavioral testing (Muller,
Grticke, Bankstahl, & Lscher, 2009). Using an animal model allows for enhanced
control of extraneous variables, co-morbidities and experimental conditions. Animal
models of human diseases are valuable when not much is known about a condition,
allowing researchers to explore potentially unrecognized problems.
The specific aims of the study were to:
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1. Define the picrotoxin-induced seizure phenotype of unrestrained as well as restrained
(stressed) mice with the SCN1A R1648H missense mutation (RH) compared to wild-type
(WT) mice (restrained and unrestrained)
2. Define the behavioral response to a number of behavioral paradigms [Open field
(anxiety and locomotion), forced swim test (depression), novel cage (response to
novelty), predator odor (anxiety), and social interaction (social stress)] in the RH mice
compared to WT mice
3. Determine the neuroprotective effects of subcutaneous injections of docosahexaenoic
acid (an omega 3 PUFA) on hyperactive behavior in RH mice.
Providing evidence of these responses in genetically altered mice that recapitulate
a human condition will help to expand knowledge of the spectrum of the phenotype in
these mice and ultimately in humans. Knowledge gained by examining omega 3 PUFA’s
as a neuroprotectant will provide evidence for use of this non-pharmacologic therapy as a
treatment for neurological morbidity. Nurses care for patients with epilepsy in multiple
settings such as hospitals, out-patient clinics, medical offices, and public health arenas.
Additionally, nurses have the prime opportunity to monitor and educate patients with
epilepsy (or familial history) regarding the negative impact of stress as well as nonpharmacologic therapies for prevention or treatment of the patient with GEFS+.
Hypotheses
The following hypotheses were proposed for this study:
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1. H1: RH mice will have increased frequency and duration as well as severity of
picrotoxin-induced seizure activity compared to WT mice,
2. H2: Restraint stress will increase the frequency and duration as well as worsen the
severity of picrotoxin-induced seizure activity in RH mice and WT mice
compared to controls (RH and WT unrestrained mice),
3. H3: The phenotypic behavioral traits in this model of GEFS+ will parallel those
traits seen in epileptic humans
4. H4: Administration of omega 3 PUFA’s to the RH mice will lead to a reduction in
perturbed behavioral traits
Theoretical Framework
Many researchers have examined the effects of stress in epilepsy; however, no
one has specifically described the impact of stress on the seizure phenotype in animals (or
humans) with the Scn1a R1648H mutation. Nor has anyone described a range of
behavioral characteristics of this mutation. Additionally, no one has examined the use of
omega 3 PUFA’s to protect against neurological outcomes (specifically hyperactive
behavior) in animals with this genetic mutation. This study will fill the gaps in these
areas. We have developed a simplistic model of stress and epilepsy (see Figures 1 and 2).
The first model represents specific aim 1 in which the first aspect is the condition. The
condition is the expression of the SCN1A R1648H mutation. As described earlier, this
mutation is found in families exhibiting, albeit with varying phenotypes, GEFS+.
Approximately 10% of GEFS+ is due to SCN1A mutations (Gambardella & Marini,
2009), and unfortunately the other 90% have unexplained symptomatology. In general, it
is reported that people with seizure disorders have higher levels of stress (Lai & Trimble,
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1997). Additionally, stress is considered one of the most frequent triggers of seizure
activity, although some animal models demonstrate conflicting results (Abel & Berman,
1993; Forcelli, Orefice, & Heinrichs, 2007). The next piece of the first model is the
insult. The insult is a stressor which in the case of this study is the use of restraint stress.
Restraint stress has been found to induce activation in the pre-frontal cortex in certain
mouse strains (O’Mahony, Sweeney, Daly, Dinan, & Cryan, 2010). Following the insult,
we assessed the outcome which is the specific seizure phenotype. Stress causes a cascade
of neurohormones which triggers the release of glucocorticoids and mineralocorticoids
(de Kloet et al., 2005; Mora, Segovia, del Arco, de Blas, & Garrido, 2012). Brunson and
colleagues (2002) state, “glucocorticoids modulate the expression and release of a
number of neurotransmitters and neuromodulators” (p. 187). Additionally, researchers
have noted that corticotropin releasing factor has pro-convulsive properties (Ehlers et al.,
1983). Therefore, we postulate that the stress the RH mice will encounter will exacerbate
their seizure response.
In the second model (see Figure 2), representing specific aim 2, the stressor is the
precipitating event. This stressor could be multiple types of stressors; however, for this
study, the stressors come in the form of novel environments, introduction to strangers or
predator odor, or being forced to swim (Bailey & Crawley, 2009; Holmes, 2003). For
this particular aim of the study, we are not looking at potential seizure activity but rather
the behavioral response to a stressor, because not every stressor in a human triggers a
seizure. The animal (with the RH mutation) encounters the stressor, and then the
behavioral outcome is noted (which is the last piece of the model). Previous research
suggests that humans with epilepsy (as well as animals) have higher levels of anxiety

14
(Ottman et al., 2011). Many human studies have also reported higher levels of
depression in persons with epilepsy (de Souza & Salgado, 2006; Ottman et al., 2011).
Therefore we infer that these mice will also exhibit signs of anxiety and depression.
Social interaction is also of importance and is considered an indicator of quality of life
(Heinrichs & Bromfield, 2008). We anticipated that these mice would have altered social
interaction in that they would also have avoidance behaviors.
The last aspect of the model (representing specific aim 3) is the intervening step
of the omega 3 PUFA’s. As depicted in the model, these PUFA’s were given from
weaning for 2 weeks. It was speculated that these omega 3’s would alter the path of the
model in that the insult would have little to no impact on the outcome. There are studies
that have examined the neuroprotective effects of omega 3 PUFA’s against symptoms of
ADHD (i.e., hyperactivity); however the results are inconsistent, and the study
methodology and subjects appear heterogeneous.
Although there is evidence of the impact of stress in epilepsy, there is a lack of
understanding of the behavioral, as well as seizure response to stress in this particular
sodium channel mutation. Additionally, there are no studies using omega 3 PUFA’s as
treatment against hyperactive behavior in an animal model of GEFS+. This study
increased the scientific evidence in all of these areas.
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Figure 1. Theory of Stress and Epilepsy (Part A)
Condition

Scn1a R1648H mutation

Insult

Stressor (restraint stress)

Seizure Outcomes

Shorter latency to seizure
More severe seizure
Longer duration of seizure

16
Figure 2. Theory of Stress and Epilepsy (Part B)
Stressor

Condition

Behavioral Outcomes

Scn1a R1648H mutation
Novel Environment

* Anxiety : Altered
grooming behavior,
decreased rearing
behavior, altered
burrowing behavior,
increased
staring/immobility

Forced Swim test

*Depression: Longer
periods of
immobility

Social interaction test

*Anxiety : Less
interaction

Predator Odor test

*Anxiety: Decreased rearing
Increased immobility

Open Field

*Anxiety: Decreased
time in center of field,
increased time spent
in perimeter,
increased
distance traveled

Omega 3 change: Locomotion
back to level of controls in
open field paradigm
INTERVENTION: OMEGA 3 PUFA INJECTIONS SUBCUTANEOUSLY FOR 2
WEEKS STARTING AT WEANING
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This study contributed to the scientific knowledge in the area of seizure and
behavioral phenotypes in an animal model recapitulating the human condition of GEFS+.
In addition, the use of omega 3 PUFA’s as a treatment for neurological sequelae in this
animal model is investigated. Data from the various paradigms used in this study may
help to improve assessment and treatment of persons with GEFS+.

CHAPTER II
LITERATURE REVIEW
A review of the literature is presented in chapter two and encompasses the
disorder of genetic epilepsy with febrile seizures plus (GEFS+), the impact of stress in
epileptic seizures as well as other behavioral manifestations of stress. In addition, a
review of omega 3 polyunsaturated fatty acids (PUFA’s) as a treatment and possible
provider of neuroprotection is discussed. Gaps in our understanding are also presented.
Genetics of Epilepsy
Researchers have been exploring genetic causes of seemingly idiopathic epilepsy.
While they believe there are multiple (unstudied) genes that affect epilepsy, there is a
large body of evidence revealing the impact of certain single genes (Escayg & Goldin,
2010). Particularly, genes that regulate or instruct voltage-gated sodium channels are a
focus of current research. These sodium channels are key to neuronal signaling
(Gambardella & Marini, 2009), and if there is a disruption within the channel, alterations
in excitation occur which can initiate seizure activity. The sodium channel, voltagegated, type 1, alpha subunit (SCN1A) is the gene that instructs the alpha subunit of the
sodium channel (Escayg & Goldin, 2010; Gambardella & Marini, 2009; Mulley et al.,
2005). SCN1A mutation is inherited dominantly and is associated with GEFS+ and
Dravet syndrome (Mahoney et al., 2009), and while 80% of Dravet cases have the
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SCN1A mutation, only 10% of GEFS+ cases have the mutation leaving the other 90% of
cases unexplained (Gambardella & Marini, 2009; Mulley et al., 2005). This emphasizes
the need for further study in regards to this seemingly inherited disorder.
There are several missense (point mutations) mutations along the SCN1A gene
associated with varying seizure phenotypes (Burgess, 2005; Zuberi et al., 2011).
Specifically, the R1648H point mutation is linked with GEFS+ and Dravet syndrome. In
GEFS+, the mutation only limits the activity of the sodium channel; however, in Dravet
syndrome, the channel has loss of function (Escayg & Goldin, 2010). This difference in
limited activity versus loss of function accounts for the range of severity of symptoms in
patients with GEFS+ and Dravet. Additionally, it is suggested that the location of the
mutation on the gene, multiple gene involvement, and environmental factors play a part
in the variations in phenotype (Mulley et al., 2005). Many people view the phenotype of
SCN1A mutation on a continuum with GEFS+ on one end and Dravet syndrome on the
other (Gambardella & Marini, 2009). GEFS+ is largely considered a familial epilepsy
with the typical phenotype being febrile seizures occurring after the age of 6 or nonfebrile tonic-clonic seizures (Gambardella & Marini, 2009).
Animal Models of Scn1a
In 2000, the R1648H missense mutation was discovered in a family with GEFS+
(Escayg et al., 2000). Since then multiple studies have examined the effects of Scn1a
mutations in animals. It is important to note the difficulty in using an animal model to
replicate a human condition with so many varying degrees of phenotypes. Nevertheless,
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researchers have been and continue to use animal models of GEFS+ and report various
aspects of the genotype and phenotype.
The Escayg laboratory has generated mouse models of the human condition of
GEFS+ by using the R1648H (RH) mutation in the SCN1A gene. Tang and associates
(2009) describe how used this mouse model and tested for seizure thresholds using kainic
acid. These mice had decreased thresholds for seizures compared to controls.
Interestingly, in the knock-in RH line, thresholds to kainic acid were normal; however,
decreased thresholds to flurothyl-induced seizures were observed (Martin et al., 2010).
They suggest the impairment of the sodium channel is in the interneurons. This same
group also report decreased seizure thresholds to high temp (febrile seizures), infrequent
spontaneous seizures, and normal lifespan (Hawkins, Martin, Frankel, Kearney, &
Escayg, 2011). Hawkins and colleagues state, “cortical interneurons from Scn1a RH/+
and Scn1a RH/RH mice display slowed recovery from inactivation, increased usedependence, and a reduced ability to fire action potentials” (p. 655). This means that
there was reduced inhibition of GABAergic interneurons which can lead to abnormal
excitability of the network. Emphasizing even further the impact of GABAergic neurons,
one study looked at the hippocampal synaptic transmission, specifically focusing on
GABAergic neurons in a rat line expressing the Scn1a N1417H mutation (Ohno et al.,
2010). In this study, they found selective alteration of GABAergic interneurons whereas
excitatory neurons were not affected. Thus, this study added to the body of evidence of
SCN1A involvement with GABAergic neurons.
The clinical presentation of GEFS+ is complex. A group of scientists studied a
large four generation pedigree to examine the various phenotypes (Mahoneyet al., 2009).
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They report a high variability that included 9 members with generalized tonic-clonic
seizures (GTCS), 2 with febrile seizures, 5 who had experienced multiple episodes of
status-epilepticus, 4 with absence seizures, 5 with intellectual disabilities, 3 with serious
psychiatric disease, and 2 persons with ataxia. Obviously there are varying ends of the
spectrum in regards to physiological symptoms and conditions in this family with
GEFS+. Burgess (2005) describes the complex process of examining genotype and
phenotype. He states that there are probably multiple genes with multiple mutations
involved in and linked to the GEFS+ spectrum. It is also suggested that the environment
plays a role in the varying phenotypes of GEFS+; however, no studies have looked at
environmental influences on genotype and phenotype of GEFS+ (Scheffer, 2011).
Because there are so many variations of phenotype, it is important to study these
mutations. It is easier to look at the impact of certain genes in animals because the
conditions can be much more easily controlled in a laboratory environment. This is why
it is imperative to use animal models to elucidate certain characteristics in a disease
model that may be difficult to isolate in humans.
Stress and Epilepsy
When a person encounters a stressful situation, the brain’s limbic system
interprets the events (de Kloet et al., 2005). If a person’s body cannot respond to stress
adequately, it may be too difficult to return to homeostasis which can be considered
reaching an allostatic load. Sometimes when a person has a genetic predisposition for
neurological issues (especially psychiatric illness), if they have reached their allostatic
load, then this may push that person ‘over the edge’ so to speak (Karatsoreos & McEwen,
2011) and trigger neurological issues (de Kloet et al., 2005). It is important to note that
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“voltage-gated ion channels’ function [are] strongly affected by corticosterone and stress”
(de Kloet et al., 2005, p. 466) although he states that calcium channels are more affected
than potassium and sodium channels.
Seizure Outcomes in Response to Stress
Although stress is considered a common trigger for seizure activity, human
studies have had a difficult time finding relationships between a stressor and seizure
activity. Bosnjak and colleagues (2002) evaluated the stress of war and its impact of
seizure activity in children. They found that the frequency of seizures in children
affected by war was higher than those not affected by war. However they also report that
qualitative data showed 10 children (total from both groups---those affected by war and
those not affected by war) who had their first seizure during the war period were linked to
a stressful event. Ten children (from both groups) had their first seizure during the war
period and were not linked to a stressful event. What is interesting is that the children
linked with a stressful event had higher number of absence seizures (considered less
severe) and children whose seizures were not linked to a stressful event had a higher
number of grand mal seizures (considered to be more severe).
Although Swinkels and colleagues’ study (1998) found that 8 out of 30 people
with epilepsy experiencing a stressful event (evacuation due to extreme flood threat)
reported an increase in seizure frequency compared to controls, 33% of those with a
change in seizure frequency had subjective reports of stress whereas 38% of those with
no change in seizure frequency had subjective reports of stress. Interestingly, Abel and
Berman (1993) found anti-convulsive effects of a stressful event. They used varying
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durations of water immersion in an animal model of epilepsy and then examined the
impact on seizure activity and corticosterone levels. The longer the immersion, the
higher the corticosterone levels, but the seizure latency to onset was increased, and these
animals had fewer severe seizures.
Behavioral Response to Stress in Epilepsy
Heinrichs and Bromfield (2008) describe how an animal model can be indicative
of behaviors in humans such as mobility, anxiety, depression, and social interaction.
They also describe typical behaviors of rodents as grooming, stretching, and exploration.
These researchers suggest the importance of a wide variety of assessment to include
motor, affective, and social aspects that could provide a good overall picture of an
animal’s somatic and psychological characteristics. This is important because the current
study addresses all three of these aspects. Activity monitoring is useful in seizure-prone
animals. Anxiety in these types of animals can be exhibited by hyper-reactivity to a
stressor or as less exploration (Crawley, 2000). Depression could be exhibited by slower
or ceased motion (Crawley, 2000). Altered social interaction may be exhibited by
decreased time spent with conspecific (another animal of the same species). It is
important to use the same gender but unfamiliar rodent when performing social
interaction tests (Heinrichs & Bromfield, 2008). The current study uses this technique
with social interaction. Heinrichs and Bromfield suggest “deficits in adaptation to stress
and novel environments may be related to the neuronal network for functional excitability
that impacts seizures” (p. 616).
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Anxiety, depression, and social stress.
Researchers used a mouse (n = 33) model of temporal lobe epilepsy (status
epilepticus induction by pilocarpine) and then evaluated their behavior and neurological
status (Muller et al., 2009). Briefly, they reported that after status epilepticus, animals
had significantly higher anxiety behavior, increased locomotion, and decreased spatial
learning and memory. Surprisingly, these animals did not display evidence of depressive
behavior. Conversely, a different group reported increased depressive symptoms
(increased immobility in the forced swim test) in their rat model using Long-Evans rats
with spontaneous spike-wave discharges but very few signs of anxiety (Shaw, Chuang,
Shieh, & Wang, 2009).
Human studies include subjective and objective assessment of stress in persons
with epilepsy. One study reports that in their study population of 66 people with
epilepsy, 44.4% had depression at some point in their life and 43.9% experienced anxiety
(de Oliveira et al., 2011). Of most concern, 7.6% had a suicide risk and the majority of
those had actually attempted suicide, although none of these measures were compared to
controls. They did report that persons with increased frequency of seizures had a higher
risk of suicide, emphasizing the psychological impact of seizure activity. The Epilepsy
Comorbidities and Health (EPIC) survey reported that in a large cohort (n = 3,488),
people with epilepsy had a higher levels of depression, anxiety, attention deficit
hyperactivity disorder, sleep disorders, and bipolar disorder compared to matched
controls (Ottman et al., 2011) although another large study found no differences in
depression between people with and without epilepsy (Novy et al., 2012). One strength
Ottman’s (2011) study was that their questionnaire asked if a physician had ever
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diagnosed them with a particular psychiatric condition (multiple conditions were listed)
rather than relying on patients’ self-report of symptoms. Another study also found higher
levels of depressive and anxiety symptoms in their population with epilepsy (n = 60);
however, they relied on patient report of symptoms (de Souza & Salgado, 2006). An
important note is that they used highly valid tools for assessment of depression (Beck
Depression Inventory) and anxiety (State-Trait Anxiety Inventory).
Alterations in the HPA axis.
A few studies have examined the HPA axis in animal models of epilepsy. A
group of researchers report that El mice (a model with spontaneous seizures) had higher
levels of corticotropin releasing factor (CRF) peptide in the paraventricular thalamic
nucleus and as well as increased blood levels of corticosterone one hour after the stress of
foot shock or tail suspension compared to controls (Forcelli et al., 2007). These
researchers did not find any alterations when the animals experienced social stress.
Ehlers and associates (1983) report that in Sprague-Dawley rats (n = 35), CRF injected
intracerebroventricularly “produced dose dependent patterns of EEG and behavioral
changes different from those seen following saline injections” (p. 333). Animals injected
with CRF also experienced seizure activity within 1-3 hours of injection. Additionally,
higher CRF doses were associated with hyperactivity, increased grooming, increased
rearing, and increased startle reaction to stimuli.
Epilepsy and γ-Aminobutyric Acid
Epilepsy has long been associated with γ-aminobutyric acid (GABA), an
inhibitory neurotransmitter. Most older studies linking seizure activity and GABA used
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pharmacological methods to either reduce GABA (to induce seizure activity in animal
models) or increase GABA (to reduce seizure activity) (Cossette, Lachance-Touchette, &
Rouleau, 2012). Over the past two decades, more information explaining genetic impact
on GABA either in regards to GABA receptors or GABAergic interneurons has been
reported (Cossette et al., 2012; Dibbens et al., 2009). However, until recently, the
interaction between mutations in the SCN1A gene and GABA has remained unknown.
Since the discovery of the important role of the SCN1A gene in epileptic
disorders, researchers have attempted to elucidate how the gene influences seizure
activity. The SCN1A gene is responsible for encoding the alpha subunit in the Nav1.1
sodium channel which is primarily expressed in the central nervous system
(http://ghr.nlm.nih.gov/gene/SCN1A). Because voltage-gated sodium channels are
critical for the initiation and propagation of action potentials among neurons (Martin et
al., 2010), it is easy to understand that disruption in these channels can alter neuronal
signaling, thus potentially initiating seizure activity. However, until recently, the
mechanism of action of the disruption in the channel that led to seizures was not
understood. In 2010, Martin and colleagues measured electrophysiological properties of
excitatory as well as inhibitory (GABAergic) interneurons in the cortex of genetically
altered mice expressing the R1648H missense mutation in the Scn1a gene and found that
the GABAergic interneurons were altered whereas the excitatory interneurons were not.
Another group of researchers used electrophysiology to examine cells in the
hippocampus of rats with a mutation in the Scn1a gene and noted that GABAA receptormediated synaptic transmission was specifically altered over other types of synaptic
transmission (Ohno et al., 2010). These animals, however, had the N1417H missense
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mutation which occurs at a different point in the Scn1a gene; therefore the dysfunction of
the sodium channel may not be the same as with the R1648H mutation. The combination
of these studies emphasizes the importance of GABAergic interneurons in the etiology of
seizure activity resulting from SCN1A mutations.
GABA and Hyperactivity
Almost one-fourth of all cortical neurons use GABA. Additionally, GABA
subtype a (GABAA) produces inhibitory effects through direct inhibition of excitatory
neurons, whereas GABAB subunits have a more indirect route of inhibition of excitatory
neurons and GABAC inhibits other GABA neurons (Tamminga, Hashimoto, Volk, &
Lewis, 2004). GABAergic neurons are found throughout the brain, and they can affect
different areas of the brain responsible for motor control such as the prefrontal cortex
(PFC), striatum, substantia nigra, hippocampus and the rostral ventrolateral medulla
(Bowman, Kumar, Hassan, McMullan, & Goodchild, 2012; Lecourtier, de Vasconcelos,
Cosquer, & Cassel, 2010; Tamminga et al., 2004)
The PFC is an extremely important area in terms of ADHD symptomatology
(Brennan & Arnsten, 2008), and multiple animal studies have examined the impact of
GABA in the PFC. When an NMDA antagonist (which reduces GABA transmission)
was injected into the PFC of adult male wistar rats, a significant increase in locomotor
activity was found while simultaneous injection of muscimol (A GABA agonist) offsets
the effects of the NMDA antagonist (Del Arco, Ronzoni, & Mora, 2011). Additionally,
researchers reported increased locomotor activity after injecting the PFC of Long-Evans
rats with bicuculline (A GABAA antagonist) (Enomoto, Tse, & Floresco, 2011).
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Homanics and colleagues (1997) examined a mouse model lacking one particular subunit
of the GABAA receptor and found several neurological changes including seizure activity
and hyperactivity. These animals had severe impairment of the GABAA receptors and
thus exhibited severe symptoms which are different compared to the disruption of
GABAergic neurons caused by the RH mutation of SCN1A. Lesions to cholinergic as
well as GABAergic neurons in the septohippocampal area produced a significant increase
in locomotor activity following an IP injection of amphetamine (Lecourtier et al., 2010)
which indicates that the altered GABAergic response (in addition to altered cholinergic
response) prevented attenuation of locomotor activity. These combined studies
emphasize the importance of GABA in relation to hyperactivity as seen in children with
ADHD.
Intervening with Omega 3 PUFA’s
General neuroprotective properties.
Animal studies.
Multiple animal and human studies have examined the impact of omega 3
PUFA’s as a treatment or neuroprotection against neurological insult or other types of
insults. One study used Fat-1 male mice (these mice can produce de novo n-3 PUFA’s
from n-6 PUFA’s) to examine if they were more resistant to pentylenetetrazol (PTZ)induced seizures (Taha et al., 2008). They found these mice had higher levels of brain
DHA than wild type littermates (WT) which persisted into adulthood as well as having
delayed seizure onset, and although p = 0.08, this may be clinically significant evidence
of some neuroprotection. Interestingly, only 44% of WT survived but 80% of Fat-1
survived; however this was not statistically significant (Taha et al., 2008). Other
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researchers used male wistar rats (n = 20) to examine the effects of daily omega 3
PUFA’s (85mg/kg fish oil) in prevention of neurological damage against a simulated
epileptic seizure using pilocarpine (Ferrari et al., 2008). They report that animals with
induced seizures who received vehicle instead of the omega 3’s had significant cell loss
in hippocampal subfields CA1 and CA3 compared to controls as well as compared to
animals with induced seizures receiving omega 3’s prior to seizure induction.
Additionally, the animals with induced seizures and omega 3 intake prior to induction
had similar number of cells in the hippocampus (CA1 and CA3 subfields) as compared to
controls (both controls receiving vehicle and omega 3’s but no seizure induction). Using
a 4:1 ratio of linoleic acid and alpha linolenic acid via IP injections daily for 21 days,
scientists tested the anticonvulsive effects with different doses (40mg/kg, 200mg/kg,
400mg/kg, and 1000mg/kg) (A. Taha, Filo, Ma, & McIntyre Burnham, 2009). The
200mg/kg dose appeared to be the most effective with a 3-fold longer latency to
pentylenetetrazol-induced seizures compared to controls and rats receiving the 40mg/kg
omega 3 dose and the 400mg/kg dose. However, there was no reported difference in
seizure severity. In adult male wistar rats (n = 20), Cysneiros and colleagues (2010)
performed a study using 85mg/kg omega 3 PUFA’s and seizure induction with
pilocarpine. The exciting results from this study are that they found preservation of
GABAergic cells which is important for the current study because SCN1A mutations
impact GABAergic neurons.
An interesting study used an animal model of epilepsy but only assessed behavior.
When comparing the differences in activity and learning in Fast rats (rats bred to be
seizure-prone) to slow rats, Gilby and associates (2009) found few differences. They
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used 18%EPA and 12%DHA (~1000mg/kg of EPA/day and 700mg/kg DHA/day) in rat
chow for approximately 3 months, and then assessed the animals on post-natal day (PND)
90 using the open field test, Morris Water maze, and restraint. The only significant
difference they reported was that the Fast rats receiving omega 3 supplementation had
decreased activity only when compared to the slow rats but not to baseline activity in the
fast rats. It is important to note the differences in this study and the current study vary
widely including genotype of animal, doses/concentrations of omega 3, and route of
administration of the omega 3 PUFA.
There are some animal studies using omega 3 PUFA’s as neuroprotection against
hypoxia and/or ischemia. One study utilized adult rats undergoing cerebral artery
occlusion that were given varying doses of DHA IV 3 hours after occlusion onset. Low
and medium doses of DHA led to neuroprotection (increased neurological scores and
decreased apoptosis in cortical and sub-cortical regions) (Belayev, Khoutorova, Atkins,
& Bazan, 2009). Interestingly, no neuroprotection was reported with higher doses of
DHA (70mg/kg). Lastly, researchers used IV injections of 500nmol/kg of linoleic acid
for 3 days prior to 6 hours of insults of either global ischemia or injection of kainic acid
(Blondeau, Widmann, Lazdunski, & Heurteaux, 2002). They report a significant
decrease (almost total inhibition) of neuronal loss in CA1 and CA3 (hippocampal areas)
compared to controls. Another study examined 7 day old rat pups who had common
carotid artery ligation (Berman, Mozurkewich, Liu, & Barks, 2009). Prior to ligation, the
pups were given varying doses of DHA, and at PND 14, the researchers tested
sensorimotor function. Pups supplemented with DHA had significantly better outcomes.

31
There are few animal studies that examine the impact of omega 3 PUFA’s on
symptoms of ADHD; however they generally assess deficiencies in PUFA’s on
locomotor activity. Lavialle and colleagues (2008) fed female hamsters either an omega
3 PUFA adequate or deficient diet during pregnancy through weaning and then continued
their male offspring on the same diet through the end of testing. At 2 months of age, the
animals were assessed for locomotor activity, and at 3 months of age striatal lipid and
monoamine levels were examined. Animals receiving n-3 PUFA deficient diets had
higher levels of locomotor activity as well as lower levels of striatal DHA. This
emphasizes that levels of n-3 PUFA’s obtained through diet directly impact brain levels.
Another study examined the relationship between spontaneous levels of locomotor
hyperactivity (as well as other symptoms of ADHD) and phospholipid fatty acid levels in
the frontal cortex in adult rats (Vancassel et al., 2007). Interestingly, there was a
significant negative correlation between n-3 PUFA level in the frontal cortex and
locomotion. These studies did not examine the impact of n-3 PUFA supplementation;
however they do provide insight into the relationship between n-3 PUFA and locomotor
activity.
Human studies.
There are multiple studies using human subjects that examine the effects of
omega 3 PUFA’s as treatments for varying insults and several of these studies investigate
uses in epilepsy. Researchers studied people (n = 5) with epilepsy (secondary to another
CNS disorder) and intellectual disability to examine if omega 3 PUFA supplements
helped improve seizure activity (Schlanger, Shinitzky, & Yam, 2002). They used a
‘spread’ consisting of 46% DHA and 18% EPA and 1% ALA daily for 6 months. Four of
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the subjects who had previously had 1-8 seizures per week, had 0-1 seizures per month
after PUFA’s. One subject that previously had 14 seizures per week had 3 seizures per
week after treatment (no statistical data given). This concentration and ratio is different
from what is normally found in the diet. Yuen and associates (2005) performed a
randomized, placebo-controlled trial in 56 subjects with refractory epilepsy (≥ 4 episodes
per mo.) to examine effects on n-3 PUFA’s on seizure activity. They used a placebo for
12 weeks, then provided omega 3 PUFA (1g EPA and 0.7g DHA daily) for 12 weeks and
reported that 5 out of 29 subjects taking omega 3’s had a 50% reduction in seizures
whereas 0 out of 27 controls had 50% reduction (p < 0.05) within the first 6 weeks of
treatment. Unfortunately this effect did not persist beyond 6 weeks. Other researchers
performed a randomized trial with humans (n = 21) that used omega 3 supplementation
(EPA:DHA ratio of 3:2) of 1.1g/day for 7 days then 1.1g/day twice per day for 13 weeks
to examine the effects on intractable focal or generalized epilepsy (4 seizures/mo or more
despite medication) and reported no decrease in seizure frequency of 50% or more
(Bromfield et al., 2008). The anti-epileptic medications and dosages that the patients
consumed varied. Lastly, a study that examined the use of high dose fish oil
(9600mg/day consisting of 2800mg of omega 3 fatty acids) in 11 people with refractory
seizures reported an increase in seizure frequency of 11%; however, the sample size is
not adequate to provide statistical power (DeGiorgio, Miller, Meymandi, & Gornbein,
2008).
There are multiple, yet inconsistent, data from human studies (mostly involving
children) regarding the impact of omega 3 PUFA’s on symptoms of ADHD.
Hyperactivity subscale scores using a parent-rated measure of ADHD symptoms as well
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as DSM IV criteria were significantly improved in children (n = 26) after 8 weeks of n-3
PUFA supplementation (20-25mg/kg/day of EPA and 8.5-10.5 mg/kg/day of DHA)
versus children with placebo (Belanger et al., 2009). It is important to note that teacher
ratings of ADHD symptoms did not differ between subjects and controls, although
parents and teachers do not always agree on rating scales for symptoms of ADHD
(Malhi, Singhi, & Sidhu, 2008). Supplements with 400mg DHA and 40mg EPA (as well
as 60mg of gamma linoleic acid, an n-6 PUFA, 80mg Mg, and 5mg Zinc) for 3 months in
810 children ages 4-15 with ADHD-like symptoms significantly improved attention,
emotional problems and hyperactivity from baseline to 12 weeks (Huss, Völp, & StaussGrabo, 2010). This study was large enough to provide adequate power of the analysis;
however, these children were not formally diagnosed with ADHD but were evaluated
using two tools that measured symptoms typical of ADHD (parent-rated). Another
randomized, double blind, placebo-controlled trial for 15 weeks with a crossover for
another 15 weeks using a PUFA supplement (93mg EPA, 29mg DHA, 10mg gamma
linoleic acid, and 1.8mg Vit. E) found improvements in parent ratings on the Conner’s
Parent Rating Scale for cognitive problems/inattention, Conner’s Global Index for
restless-impulsive behavior, and the DSM IV subscale of inattentive and hyperactiveimpulsive as well as oppositional behavior in the supplement group but not the placebo
group (Sinn & Bryan, 2007). There were no differences in teacher ratings on any
subscale.
One study examined the effects of EPA (500mg/day) exclusively and noted
improvements in teacher-rating scale of inattention in children ages 7-12with ADHD as
well as the combined parent/teacher ratings in children with oppositional behavior for
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inattention and oppositionality; however, no improvements were noted for the
hyperactivity scores (Gustafsson et al., 2010). This study only used EPA in the
supplement, and compared to other studies that have shown efficacy of n-3 PUFA
supplementation on hyperactivity scores, those studies used a combination of EPA and
DHA (as well as other substances), which suggests that DHA may impact locomotor
activity more than EPA.
Conversely, no effects on ADHD behaviors were noted in children ages 6-12 with
either ADHD or suspected ADHD after two months of eating food enhanced with fish oil
(n = 20) (equated to 3.6gram DHA/week and 700mg EPA/week) compared to those not
eating the enhanced food (n = 20) (Hirayama, Hamazaki, & Terasawa, 2004). It is
difficult to compare these results with other studies in which all of the subjects had
formal diagnoses of ADHD. One study that did use children with a confirmed medical
diagnosis of ADHD found no improvement in children (n = 49) who either took DHA
345mg/day or placebo even though serum phospholipid DHA levels increased (Voigt et
al., 2001). One reason for this finding, however, could be that the researchers stated
these children were all ‘effectively medicated’ prior to initiation of the study.
There seems to be heterogeneity among the studies including age of subjects,
length of supplementation, dose, concentration, and type of n-3 PUFA. Additionally, the
quantification of ADHD symptoms varies from study to study. Fortunately, nearly all of
the studies report few to no side effects of supplementation with dyspepsia, the aftertaste
of fish and inability to swallow pills as the main complaints (Johnson, Ostlund, Fransson,
Kadesj, & Gillberg, 2009; Milte, Parletta, Buckley, Coates, Young, & Howe, 2012)
which indicates the relative ease of use in scientific research. Although many individual
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studies do not report significant effects of DHA or other n-3 PUFA’s on hyperactivity or
other symptoms of ADHD, a meta-analysis conducted by Bloch and colleagues (2011)
concluded that there was a “small but significant” effect of n-3 PUFA’s on hyperactivity,
although EPA appeared to be the most significant. These researchers felt that maybe that
the individual studies may have been under-powered or have other methodological issues.
Administration of omega 3 PUFA’s.
Whenever an agent, even a complimentary medicine, is used in an experimental
design, it is important to consider dosage, route, and timing of administration. In 2005,
Yuen and colleagues found results in their human study with 1.7g n-3 PUFA (1g EPA
and 0.7g DHA daily), but seizure improvement was short-lived. They speculated that the
dose was too low. Another set of researchers found dose-dependent anticonvulsant
effects using a combination of linoleic acid and alpha-linolenic acid (4:1 ratio) (Taha et
al., 2009). The dose of 200mg/kg seemed to be the most efficacious as well as
minimized abdominal bloating and weight loss issues in rodents. One animal study found
that 14mg/kg of DHA worked the best in preventing apoptosis or neurological damage
from middle cerebral artery occlusion (Belayev et al., 2009). Another study utilized
400mg/kg of DHA to examine effects on PTZ-induced seizures (Taha et al., 2010). Yet
another study used DHA 12mg/kg to examine impact on kindled seizures (Musto,
Gjorstrup, & Bazan, 2011). Human studies are similarly inconsistent with ranges of
DHA between 500mg/day to 1200mg/day or more (Campoy et al., 2011; Helland et al.,
2008). Interestingly, a group studied plasma fatty acid levels in patients on
carbamazepine (an anti-epileptic agent) and found the patients had lower levels of omega
3’s even after they were given omega 3 supplements than patients on oxcarbazepine
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(Yuen et al., 2008). Therefore it is important to consider whether or not patients are on
anti-epileptic medications when giving omega 3 fatty acids. Some patients are on
multiple medications which could further impact omega 3 levels.
The route of omega 3 PUFA administration varies widely among animal studies
and includes oral (via the chow) (Willis, Samala, Rosenberger, & Borges, 2009),
intraperitoneal injections (Taha et al., 2009), subcutaneous injections (Taha et al., 2010),
as well as intravenous injections (Musto et al., 2011). Human studies have consistently
used oral intake of omega 3 PUFA’s in studies. Sinha and colleagues (2009) report
increased levels of omega 3 fatty acids in the neonate after omega 3 fatty acid
supplementation during pregnancy suggesting the ability of n-3 PUFA’s to cross the
placenta. Dyall (2011) states there are inconsistencies regarding dosage, route and
combinations of omega 3 PUFA’s in various research studies. Additionally, researchers
must be careful with storage (degradation of the n-3’s) and preparation (high heat
degrades the n-3’s), and specify route of administration as well as dosage (must be
careful to specify the ratio and exactly what is in the preparation).
Mechanism of action.
Phospholipid bilayer.
There is emerging evidence for the mechanism of action of omega 3 PUFA’s as
neuroprotection or treatment for neurological injuries, but there is still more research
needed in this area. This first mechanism of action involves the lipid membrane. The
lipid bilayer of cell membranes has a critical function in cell signaling. This layer
prevents ions and other molecules from entering or leaving a cell until the correct
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moment (Lundbaek, Collingwood, Inglfsson, Kapoor, & Andersen, 2010). Dysfunction
of this membrane causes premature or delayed compartmental shift of ions leading to cell
dysfunction. DHA is reported to modulate cell membrane properties (Schuchardt et al.,
2009; Taha et al., 2010). Specifically, DHA is mainly localized to the lipid bilayer
compartment of cells (Yavin, 2006). DHA helps various membrane proteins, such as
receptors, channels and enzymes, to function properly (Mourek, Langmeier, & Pokorny,
2009). This appears to be the result of improved elasticity of the membrane (Bruno,
Koeppe, & Andersen, 2007; Sogaard et al., 2006). When proteins located within the
membrane undergo conformational changes, they exert energy on the lipid bilayer which
can result in deformation of the bilayer to a certain degree. If the bilayer is ‘stiff’ (less
elastic), then the deformation is greater thus impairing protein function (Bruno et al.,
2007) (see Figure 3). This emphasizes the importance of the need to examine the impact
of omega 3’s in the central nervous system (CNS).
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Anti-inflammation
Taha and colleagues (2010) suggest that omega 3 PUFA’s also have antiinflammatory properties. In addition, Schuchardt and associates (2009) state that PUFA
deficiency could lead to abnormal immune response which could also be a potential
mechanism for action. Spirer, Koren, Finkelstein, and Jurgenson (1994) speculate
that,“n-3 polyunsaturated fatty acids reduce the synthesis of IL-1, the main molecule
responsible for fever…” p.43. Additionally, one study found that prenatal DHA and EPA
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decreased inflammatory markers in the neonatal rat pup (Zhang, Hu, Yang, Gao, & Chen,
2010). One human study reported that a 12 week placebo-controlled RCT using omega 3
PUFA supplements in healthy medical residents had a 14% lippopolysaccaride-induced
interleukin 6 (an inflammatory marker) production (Kiecolt-Glaser, Belury, Andridge,
Malarkey, & Glaser, 2011).
Neuroprotectin D
There is also emerging evidence regarding the impact of Neuroprotectin D
(NPD1). Neuroprotectin D (Belayev et al., 2009) is believed to be a signaling molecule
with anti-inflammatory and anti-apoptotic properties (Bazan, 2006; Bazan et al., 2011;
Lukiw & Bazan, 2006). A group of researchers utilized retinal pigment epithelial cells to
demonstrate the synthesis of NPD1 after DHA was added to these cells (Mukherjee,
Marcheselli, Serhan, & Bazan, 2004). They suggest that DHA is a precursor to NPD1.
Gaps in our Understanding
The purpose of this study was to build upon animal models of genetic epilepsy
with febrile seizures plus (GEFS+). The gaps in our understanding of the human
condition of GEFS+ include behavioral phenotypes as well as the seizure response to
stress. In addition, very little information regarding the use of neuroprotectants against
co-morbid traits such as hyperactivity is reported. This study will help to fill these gaps
in the literature. Results from this animal model will permit us to extrapolate data to
humans with GEFS+, allowing us to further explore previously unknown phenomenon.
Additionally, specific treatment and preventative techniques may be employed in the
human population, thus decreasing morbidity and improving quality of life.

CHAPTER III
METHODOLOGY
Chapter three consists of a description of the design for the study. The study
sample as well as details of each experimental paradigm is included. Lastly, the plan for
analysis of the data is presented.
Research Plan
Research Design and Methods
A descriptive, experimental design used restraint stress as well as other behavioral
tests to investigate specific seizure phenotypes as well as behavioral responses in a mouse
model of genetic epilepsy with febrile seizures plus (GEFS+). All mice were genotyped
and housed using standardized Emory animal care and use protocols
(http://www.dar.emory.edu/HOME/index.php). Mice were selected for each experiment
by another researcher in the Escayg lab to make sure the appropriate numbers of subjects
and controls were tested, but I was blind to the genotypes of the mice. One group of mice
underwent seizure induction using picrotoxin. Another set of mice underwent behavioral
testing. A third set of mice received SQ injections of docosahexaenoic acid and
underwent locomotor testing at post-natal day (PND) 35. All experiments were
completed under the approval of the Institutional Animal Care and Use Committee at
Georgia State University and Emory University (see Appendices E and F).
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Description of the Genetically Engineered Mice in this Study
Escayg and colleagues (2000) discovered the R1648H missense mutation in a
family with GEFS+. In 2010, Dr. Escayg’s lab was able to genetically engineer the
C57BL/6J mouse by knocking in the R1648H (RH) missense mutation on the Scn1a gene
(see Figure 4) (Martin et al., 2010). The animals in this study are heterozygous for the
mutation and only have partial dysfunction of the channel. While these particular mice
have had testing regarding seizure phenotype (Hawkins et al., 2011; Martin et al., 2010),
they have never had extensive behavioral testing done, nor has the impact of stress on
seizure phenotype been assessed in the RH mice. C57BL/6J mice (see Figure 5) were
selected for this study because they are commonly used in laboratory testing (especially
behavioral testing) and are considered good for examining genetic modification (Muller
et al., 2009).
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Figure 4 The location of dysfunction within the sodium channel from the R1648H
missense mutation

Adapted From
http://www.nature.com/nature/journal/v409/n6823/images/409988aa.2.jpg

Figure 5 Photograph of the C57BL/6J mouse

Source: http://www.brc.riken.go.jp/lab/animal/images/mn050531_0101.png
The wild-type mice were originally obtained from Jackson Laboratories (Bar
Harbor, Maine). Male mice were used for specific aims I and II to control for any
hormonal variations that might impact the data. For specific aim III, both male and
female mice were used.
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When the pups were 12 days old, they underwent genotyping (Appendix D) and
were tagged for identification purposes to confirm their genetic mutation and logged in a
separate notebook for future data purposes. All of the mice in each experiment were born
from the 12th generation of mutants which ensures purity of the genetic mutation, and
they weighed an average of 25grams. For specific aim I and II, all testing was conducted
at PND 90. This age is considered adulthood for mice, a time after brain development
has occurred (Crawley, 2000). For specific aim III, testing was completed at PND 35.
Animal Setting
All animals were maintained in a specialized facility for small laboratory animals.
Emory University’s Division of Animal Resources and Institutional Animal Care and Use
Committee (IACUC), as well as Georgia State University’s IACUC, approved all
experiments and procedures in this study. Laboratory animals had corn cob bedding,
water and standard chow ad libitum. The environment and had controlled temperature
and humidity. The animal’s normal circadian rhythm runs on a twelve-hour light/dark
cycles (0700-1900 is lights on; 1900-0700 is lights off) and this cycle was maintained
(http://pubs.niaaa.nih.gov/publications/arh25-2/85-93.htm). Mice will sleep during the
day and stay awake during the night (http://pubs.niaaa.nih.gov/publications/arh25-2/8593.htm). The mouse’s normal sleep time is appropriate for behavioral testing because
this is a period of time when the animal is calm. Also, because the testing is done in a lit
room, it is appropriate to perform tests during the animal’s normal ‘lights on’ time so
their circadian rhythm is not altered (http://pubs.niaaa.nih.gov/publications/arh25-2/8593.htm). Emory laboratory personnel, as per routine guidelines for laboratory

44
maintenance and safety (http://www.dar.emory.edu/HOME/index.php), cared for animals
in between testing.
Specific Aim I: To establish the picrotoxin-induced seizure phenotype of
unrestrained as well as restrained (stressed) R1648H (RH) mice compared to wildtype (WT) mice (both restrained and unrestrained).
Rationale. There are data that demonstrates the reduced threshold for febrile-induced
seizures as well as to flurothyl-induced seizures (Martin et al., 2010); however, the full
extent as to the impact of stress in induced seizures is not understood. Multiple human
studies report that stress is the most common trigger of seizure activity (Bosnjak et al.,
2002; Ottman et al., 2011); however, it is difficult to ascertain if the stress was the actual
trigger, or if the stress lead to sleep alteration which is also shown to be a trigger. None
the less, a retrospective study attempted to control for effects of confounders and report
that stress was an independent trigger for seizures in people experiencing a traumatic
evacuation from their home (Swinkels et al., 1998). In regards to animal studies, there
are conflicting results reporting some anti-convulsive effects as well as pro-convulsive
effect of stress. For example, Abel and Berman (1993) report that seizure latency
increased with increasing duration of water immersion. However, pro-convulsive effects
of stress were reported in an animal model of epilepsy in response to tail suspension
(Forcelli et al., 2007). This aim addressed the conflicting data and gaps in the literature
regarding the seizure phenotype of the RH mouse in response to stress. Data from the
Escayg lab revealed that C57BL/6J mice with the RH mutation have decreased thresholds
to flurothyl-induced seizures (Martin et al., 2010); therefore, we used the RH mice to
examine picrotoxin-induced seizure phenotypes in response to stress. The use of
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picrotoxin allows the researcher to examine a broad spectrum of the seizure phenotypes
including types and durations of different seizure activities (see measures below).
Experimental Design
Cohorts.
We established 4 cohorts of mice that were distinguished by their genotype and
stressed condition: RH (stressed and unstressed) versus wild-type (WT) (stressed and
unstressed). At PND 90, these two cohorts were randomly and evenly divided (by
another researcher; therefore, this researcher was blind to the genotypes) into ‘stressed’
and ‘unstressed’ animals (n = 12 for each of the four separate groups). One week prior to
all testing, the animals were single-housed and maintained in standard housing with water
and rodent chow available ad libitum. During experimentation, the room was quiet and
controlled for environmental conditions that may induce stress. Every effort was made to
minimize animal suffering.
Seizure-induction protocol.
There were a total of 8 groups of animals consisting of 6 animals each (24 RH
mutants and 24 WT littermates---12 stressed and 12 unstressed for each genotype) so that
during testing only 6 animals underwent experimentation at a time. All tests were
performed in the morning between the hours of 0900 and 1200 to maintain consistency
and control for any impacts from hormonal circadian changes. This is also during the
sleep cycle of the mouse; therefore, they should be calm and quiet during this period
which would reduce any concern for confounders of activity level. Two hours prior to
testing, the animals were moved to the experimental room to allow them to acclimate to
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the new room and to settle down from the movement of their cages. During
experimentation, a researcher randomly but evenly assigns a few ‘stressed’ animals and
‘non-stressed’ animals to be in each group during testing. The stressed animals
experience restraint stress by being placed in a small tube in which they were not able to
move. The restraint lasted 20 minutes. The animals were then, one at a time, removed
from the tube, weighed, and then injected with picrotoxin at a concentration of 5mg/kg
via injection into the peritoneum. This particular dose was found by researchers in the
Escayg lab to be an effective dose for initiating seizures as well as not being toxic to the
RH mice. The researcher used aseptic technique in the injection process. Each dose was
calculated based on the weight of the mouse and was adjusted accordingly (all mice were
injected with the same concentration). The mice were then placed in a clear plexiglass
box for observation. Care was taken to ensure accurate identification of the animal when
it was placed into a novel environment. This makes certain that the genotype of the
animal can be traced once data collection is complete. To ensure accurate recording of
the data, each animal was videotaped for one hour using a Cannon ZR850x camera
placed on a tripod. Animals that were not placed in restraint stress underwent the same
procedure as above with the exception of the stressor. Once the hour of observation was
completed, the animals were removed from the plexiglass box and returned to their cage.
Care was taken to ensure consistency with each step of the procedure to maintain control
as well as to minimize suffering of the animal.
Measures.
The animals were videotaped for one hour to examine the picrotoxin-induced
seizure phenotype. During experimentation, the researcher observed the mice and took
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notes for future references to when times of possible seizure activity occurred. After all
experimentation was completed, the researcher viewed the videotapes and calculated the
times for latency to each type of seizure activity (as described below), length of seizure
activity, numbers of different types of seizure activity as well as the specific type of
seizure activity. Internal consistency was established by having the main researcher’s
observations confirmed by blinded observations from another researcher in the Escayg
lab for the first several mice. Additionally, the main researcher observed several of the
videos on more than one occasion to make sure consistency in recording the data was
maintained. All data was recorded and calculated by the main researcher. All data was
recorded on a flow chart (see Appendices A and B) and in a laboratory book as well as on
a secured Excel file. All calculations were double-checked for accuracy.
Myoclonic jerk.
Each mouse was observed for the first myoclonic jerk. The myoclonic jerk is the
first sign of impending seizure activity (Papandrea, Kukol, Anderson, Herron, & Ferland,
2009). The neurons are starting to have increased excitation, and the myoclonic jerk
comes prior to any type of partial or generalized seizure. The frequency of myoclonic
jerks was also calculated by dividing the total number of myoclonic jerks by the total
time recorded.
Partial or generalized seizure.
Another measure of seizure phenotype is latency to partial or generalized seizures.
Partial seizures are seizures involving only a specific area of the brain and generalized
seizures are global and cause a loss of posture (http://www.epilepsyfoundation.org/).
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Partial seizures are also classified as a focal seizure in which only a small part of the
body exhibits clonus (usually the jaw, head movement or one forelimb). Bilateral
forelimb clonus is also considered a partial seizure with more significant brain
involvement consisting of both forelimbs rapidly moving. Generalized tonic-clonic
seizures (GTCS) are a more severe type of seizure. This type of seizure activity includes
massive intermittent muscle contraction causing the animal to literally bounce around the
box. Each of these types of seizures was recorded for latency to onset, frequency and
duration. The frequency was calculated by dividing the total number of seizures (partial
and generalized calculated separately) by the total time recorded.
Hind limb extension.
Occasionally after a severe or prolonged seizure, the mouse will have hind limb
extension. The back legs will extend and stiffen as straight as possible in relation to the
body. Mice can recover from hind limb extension or sometimes they expire after this.
Sometimes the animal that recovers will continue to have generalized seizures or GTCS.
These were recorded as either present or absent.
Status epilepticus.
Other measures include whether or not the animal experienced status epilepticus
with consists of a seizure lasting greater than 15 minutes. Field notes included any sort
of aberrant activity during the recording.
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Seizure severity.
Seizure severity can be measured by recording the total time observed in seizure
activity. Because some animals died during the seizure paradigm, we also calculated the
total percentage of observed time spent in seizure activity including both partial and
generalized seizures. A modified Racine scale was also used to determine the highest
level of seizure activity experienced by each animal (Racine, 1971). See Appendix A for
the modified Racine Scale used for this study.
Fecal Boli.
The number of fecal boli was measured because increased number of boli may
signify anxiety-like behavior (Crawley, 2000). After the test, the number of fecal boli
was counted and recorded for further comparison.
Sample Sizes and Statistical Analysis
This aim generated 4 groups of mice (WT stressed and unstressed and RH
stressed and unstressed) to examine the picrotoxin-induced seizure phenotype. The
subdivision was done so that an even number from all four subsets occurred (this
researcher was blinded to the genotype). Based on values derived from prior studies in
the Escayg Lab, we determined that 48 animals (12 in each subset) would provide an
alpha of 0.05 and statistical power of 0.80. We sought to minimize the number of
animals needed for the project. If insufficient power was detected at the end of
experimentation, additional animals were studied. Due to multiple groups of animals, we
used 2-way ANOVA with Tukey’s post-hoc analysis. Additionally, all data were
assessed using the Grubb’s test for outliers as well as descriptive statistics to obtain
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mean, standard deviation and standard error of the mean. Each measure was analyzed
separately. Additionally, a p < 0.05 was considered statistically significant.
Specific Aim II: To establish the behavioral response to stress using multiple
behavior experiments in the RH mice compared to WT mice.
Rationale. There are studies that have examined the behavioral response to stressful
events in animals with epilepsy; however, the data are limited. One study reported
depressive behaviors in rats with spontaneous spike-wave discharges, but did not really
find any abnormality with anxiety (Shaw et al., 2009). Conversely, a study reported
increased anxiety but lower depressive symptoms in mice with pilocarpine-induced status
epilepticus (Muller et al., 2009). These conflicting data emphasize the need for further
study. And although Muller and associates (2009) used the C57BL/6J mouse for their
model, these mice did not have a sodium channel mutation; therefore it is somewhat
difficult to extrapolate results. Preliminary data from the Escayg lab (unpublished data)
found altered behavioral responses to predator odor and novelty environment in the
C3HeB/Fe mouse which has Scn8a (another sodium channel) mutation; therefore we can
speculate that another model of sodium channel mutation may have altered behavioral
responses. This aim will fill the gaps in the knowledge of behavioral response to various
stressful events in the RH mouse.
Experimental Design
Specific aim II involves a longitudinal design because each animal was subjected
to various behavioral paradigms over a period of time. All animals within each genotype
were randomly assigned to an experimental group because only 6 animals can be tested in
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one day. However each animal underwent the same routine of behavioral testing as
described below.
Table 1 Groups 1-4: A separate group of animals (n = 6 each) undergoing each specific
behavioral paradigm
Behavioral

Week

Week 2

Week 3

Week 4

Week 5

Week 6

Week

Week 8

Week

Week

Paradigm

1

9

10

Open

Group

Group

Group

Group

Field

1

2

3

4

Forced

Group

Group

Group

Group

Swim

1

2

3

4

Novelty

Group

Group

Group

Group

Cage

1

2

3

4

Social

Group

Group

Group

Group

Interaction

1

2

3

4

7

Cohorts.
Two cohorts were created for these experimental paradigms. One cohort was
comprised of RH mice (n = 12) and the other cohort was wild-type (n = 12). At PND 90,
these mice underwent multiple behavioral paradigms, with each paradigm being
separated by 2 weeks to reduce chance of stress resulting from one paradigm impacting
the next paradigm (see Table 1). The paradigms include the open field test, forced swim
test, novelty environment, and social stress test. Performing multiple behavioral
paradigms reduces the number of animals needed for the experiment. Additionally, one
group of animals (n = 20, 10 RH and 10 WT) underwent testing using the predator odor
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paradigm. It was decided to use this paradigm on a separate group of animals because of
the extensive nature of the test (see measures below). One week prior to the beginning of
testing, the animals were single-housed and maintained in standard housing with water
and rodent chow available ad libitum. During the entire behavioral testing process, the
animals remained single-housed and then were sacrificed at the end. During
experimentation, the room was quiet and controlled for environmental conditions that
may induce stress. Every effort was made to minimize suffering of the animals.
Protocol and measures.
All measures were observed by the researcher during experimentation; however,
each test was video-taped so the researcher could review each test to ensure accuracy of
recording of data. Internal consistency for recording data was maintained in the same
manner as described in specific aim I with the only exception being that behavioral
phenotypes were observed in this second aim as opposed to seizure phenotype in specific
aim I. Many of the data was coded by computerized software [Anymaze software from
Stoelting Co. (Illinois)].
Open field.
There was a total of 4 groups of animals consisting of 6 animals each (total of n =
12 for RH mutants and n = 12 for WT littermates, all randomly selected). All behavior
paradigms were performed in the afternoon starting between the hours of 1200 and 1400.
At each time of testing, only 6 animals underwent experimentation in order to maintain
the window of time of 4 hours to maintain consistency and control for any hormonal
circadian changes. This is also the sleep cycle of the mouse; therefore, they should be
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calm and quiet during this period which would reduce any concern for confounders of
activity level. Two hours prior to testing, the animals were moved to the experimental
room to allow the animals to acclimate to the new room and to settle down from the
movement of their cages. Each animal was placed into the center of a 24 in. x 24 in.
opaque plexiglass box with smooth cardboard bottom. Using a video camera (Cannon
ZR850x), the mice were tape-recorded for 15 minutes to examine their locomotor and
behavioral response to a novel open field environment. Once the 15 minutes had
surpassed, the animal was removed from the box, fecal boli were counted, and the area
was cleaned prior to introducing the next animal.
We examined four measures in the open field test. The first was the total duration
of time spent in the center. Generally, mice like to explore a new environment, and time
spent in the center is indicative of normal exploratory behavior (Heinrichs & Bromfield,
2008). The second measure was total duration of time spent in the perimeter of the field.
More time spent in this area is suggestive of anxiety-like behavior. The third measure
was the total distance traveled. This allowed examination of locomotor activity. We
used Anymaze software from Stoelting Co. (Illinois). Using the software allowed for
rigor, consistency, and accuracy of measurements. The fourth measure was the number
of fecal boli. Under stressful conditions mice tend to have increased fecal boli.
Forced swim test.
The second paradigm in the behavioral testing was the forced-swim test (see
Figure 6). As stated earlier, this test was conducted two weeks after the open field test.
Timing and pre-experimental protocol was the same as stated above. A large glass
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beaker was filled with approximately 3500 mL of water that was room temperature (25°C
± 1°C). The animal was placed in the center of the container and videotaped (Cannon
ZR850x) for 10 minutes. Once the experiment was completed, the animal was removed,
dried and returned to the housing unit. The temperature of the water was analyzed prior
to each animal and was adjusted as needed. Additionally, the water was changed after 3
animals.
Figure 6 Mouse undergoing Forced Swim Test

There were only two measures that were assessed during the forced swim test:
total time spent immobile and total time spent struggling. Immobility during this test is
considered a sign of depression and has been used by many researchers in tests for
depression as well as anti-depressant medications (Castagné, Moser, Roux, & Porsolt,
2001; Crawley, 2000). Active struggling (as defined by active movement of forelimbs
and hind limbs and vertical direction of the animal’s body) was recorded as well. We
used Anymaze software from Stoelting Co. (Illinois). The researcher calculated the total
time spent in active struggling with the help of Anymaze software. Using the software
allowed for rigor, consistency, and accuracy of measurements.
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Novelty cage.
The third behavior paradigm was the novelty cage. Even though the open field
test was a new environment, the novelty cage experiment allowed us to examine other
behaviors that we could not see in the open field test. This test was performed two weeks
after the forced swim test. Timing and pre-experimental protocol was the same as stated
above. Each animal was placed in a new 12.2 in. x 6.5 in. cage with new corn cob
bedding and videotaped (Cannon ZR850x) for 15 minutes. Once the experiment was
completed, the animal was removed, and fecal boli were counted. Each animal was
placed in a completely separate cage for the testing.
There were several measures that were examined during the novelty cage
experiment (Appendix C). The first measure examined the frequency of ‘stretch-attend’
movement. This behavior is characterized by the mouse keeping the hind limbs in place
but stretching forward with upper body to examine an area. Stretch-attend behavior is a
sign of anxiety because the mouse does not want to leave its original position to explore
(Bailey & Crawley, 2009). The second measure was the frequency of grooming behavior
and the third measure was the duration of grooming behavior. A normal behavior of
rodents is to self groom, and any anxiety or altered behavioral state could change the
frequency and duration of grooming (Heinrichs & Bromfield, 2008). The fourth measure
was frequency of rearing behavior with wall touch which indicates exploratory behavior
(normal in a mouse) (Bailey & Crawley, 2009). The fifth measure was the total duration
of burrowing activity. Burrowing is a natural behavior for mice and stressful situations
may alter this activity (Thomas et al., 2009). The sixth measure was the total duration of
staring. Staring is considered a response to a threat and higher anxiety (Heinrichs &

56
Bromfield, 2008). The seventh and last measure was the number of fecal boli. Increased
number of fecal boli can be indicative of anxiety-like behavior (Crawley, 2000).
Social Interaction Test.
Another behavioral paradigm that was used is the social interaction test (see
Figure 7). This test was performed two weeks after the novelty cage environment.
Timing and pre-experimental protocol was the same as stated above. A large, clear
plexiglass box was used for this experiment (see Figure 8). Below is a diagram with
measurements of the box. First, the test mouse was placed in the center of the box for 10
minutes. Then a ‘stranger’ conspecific (C3HB/Fe) wild type mouse was placed into one
of the corner boxes for 10 minutes. Each corner box has holes to allow the test mouse
detect the odor from the conspecific. Then another ‘stranger’ conspecific (C3HB/Fe)
wild type mouse was placed in the other corner box for 10 minutes. Each stranger mouse
was used twice in the entire set of 6 animals and was placed in the opposite corner from
the first time it was used. The total time for this experiment was 30 minutes and was
videotaped with the Cannon ZR850x camera the entire time. Once the experiment was
completed, the animals were removed and fecal boli were counted. The boxes were
cleaned between each animal.
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Figure 7 A photograph of the Social Interaction Paradigm with all 3 mice

Stranger 1 mouse

Stranger 2 mouse

Figure 8 Diagram and measurements of the Social Interaction box
61 cm
8.25cm X 8.25cm
41 cm

27 cm

27 cm

22 cm high

There were several measures that were examined in the social interaction test.
First, the total duration of time spent in the center of the box was calculated. We also
examined locomotor activity for the animal when no stranger was present. This allows us
to compare data found in the open field paradigm regarding locomotor activity. To detect
if the animal preferred social interaction with a stranger mouse versus an empty area
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(sociability), we recorded the time spent and number of entries into the large segmented
zone that held the stranger mouse (1/3 of the total area). The first stranger is the actual
‘stranger’ for the first 10 minutes of stranger introduction. When the second stranger was
introduced, the first stranger became the ‘familiar’ and the second stranger became the
‘new stranger.’ To determine if the mouse preferred a ‘new’ stranger mouse over the
‘old’ stranger mouse (social novelty), we examined the interaction of both the RH
mutants and their WT littermates with the novel stranger mouse compared to the older
(thus more familiar) stranger mouse. Normally, mice would investigate new mice placed
into their environment. Increased time spent away from the stranger is considered a sign
of anxiety (Heinrichs & Bromfield, 2008). Another measure was the number of
approaches within the perimeter of the stranger box when the stranger mice were present.
This gave another quantitative measure of exploration of the conspecific. We used
Anymaze software from Stoelting Co. (Illinois) to record data. Using the software
allowed for rigor, consistency, and accuracy of measurements. Lastly, the number of
fecal boli was counted.
Predator odor test.
The last behavioral paradigm was the predator odor test. As stated above, the
predator odor test was completed on a separate set of animals (n = 20) due to the
prolonged nature of the experiment. All of the predator odor experiments were
conducted in the morning, starting between the hours of 0800 and 1000. Preexperimental protocol was the same as stated above. On the first day of the protocol, the
mouse was placed into a clear plexiglass box (10.75 in. deep, 10.75 in. wide, 11.25 in.
high) for 15 minutes to become familiarized with the environment (this was done to
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control for novelty). On the third day (there was a day separating each phase of this
experiment), the mouse was placed in a different but identical box but this time with
predator odor (trimethylthiazoline 1%) for 15 minutes. On the fifth day of the protocol,
the animal was placed in the same plexiglass box with no odor for 15 minutes. Each
phase of the experiment was videotaped. Once each phase of the experiment was
completed, the mouse was removed and the box was thoroughly cleaned and air-dried.
There were two measures assessed during the predator odor test. The first
measure was the total duration of freezing. Freezing is a defensive behavior and is
expected to some degree in response to a predator (Janitzky et al., 2009). The other
measure was total duration of grooming which is a non-defensive behavior. We used
Anymaze software from Stoelting Co. (Illinois). Using the software allowed for rigor,
consistency, and accuracy of measurements.
For all behavioral measures not indicated as being analyzed by the Anymaze
software, the researcher analyzed and recorded the data for each mouse
Sample Size and Statistical Analysis
This aim generated 2 cohorts of mice to examine the behavioral response to
multiple paradigms (which were in themselves stressors) in RH or WT mice. The
researcher was blind to genotypes during all testing. Based on previous research and the
experience of the Escayg lab, it was determined that 24 animals (n = 12 RH mutants and
n = 12 WT mice, 4 groups of 6 in each test set) would be sufficient to provide power to
the analysis as well as statistical significance. Performing multiple tests on the same set
of animals also minimizes the number of animals needed for the project to ensure
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conservation as best as possible. Because the predator odor test must be conducted on a
separate set of animals, we used a conservative number (n = 20, 10 per group). For the
open field paradigm, novelty cage paradigm, forced swim test, and the total measures in
the empty box for social interaction paradigm, an independent t-test was used to analyze
data from the two groups. A repeated measures two-way ANOVA was used to analyze
social interaction (sociability and social novelty) and predator odor data. For all tests
using ANOVA, post-hoc analysis was also conducted using Tukey’s test. Additionally,
all data were assessed using the Grubb’s test for outliers as well as descriptive statistics to
obtain mean, standard deviation and standard error of the mean. Each measure was
analyzed separately. Lastly, a p < 0.05 was considered statistically significant. All of the
data were analyzed using Sigmaplot 11.0 software.
Specific Aim III: Determine the neuroprotective effects of subcutaneous injections
of docosahexaenoic acid (an omega 3 PUFA) on hyperactive behavior in RH mice.
Rationale. The available data from human studies report varying degrees of efficacy of
omega 3 PUFA’s as treatment for symptoms of ADHD. Additionally, the subjects and
methods appear to have variability. There are few animal studies assessing the efficacy
of n-3 PUFA’s on hyperactive behavior, and none of these include studying the effects of
n-3 PUFA’s on neurological sequelae in GEFS+. Therefore, we chose to assess the
potential neuroprotective effects of omega 3 PUFA’s in this animal model of GEFS+.

61
Experimental Design
Cohorts.
Six groups were created for this experimental paradigm. Two groups were
comprised of mice (both RH mutants n = 10, and WT mice, n = 10) receiving
subcutaneous injections of DHA 100mg/kg for 2 weeks starting at PND 21 (time of
weaning). Two groups consisted of control mice (both RH mutants n = 10, and WT
mice, n = 10) receiving subcutaneous injections of vehicle (oleic acid 100mg/kg) for 2
weeks starting at PND 21 (time of weaning). The final two groups consisted of control
mice (both RH mutants n = 10, and WT mice, n = 10) that did not receive any injection
and were considered as ‘unhandled controls.’ Both the DHA and oleic acid come from
Sigma-Aldrich Products, St. Louis, MO. Once the pups were weaned, they were
randomly divided into cohorts (evenly distributed between RH mutants and WT group).
The pups from each cohort (both male and female) underwent behavioral testing using
the open field paradigm at PND 35. The pups remained in group-housed standard cages
with water and rodent chow available ad libitum. During experimentation, the room was
quiet and controlled for environmental conditions that may induce stress. Every effort
was made to minimize suffering of the animals.
Protocol.
Starting at weaning (PND 21), each pup was injected SQ with either DHA
100mg/kg or vehicle (Oleic acid 100mg/kg) or remain unhandled for 14 days. Aseptic
technique was used for each injection, and injection sites were either in the scruff of neck
or on the back. On day 15, each pup underwent the open field test. The open-field
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protocol was the same as described earlier except that animals were group-housed after
weaning instead of single housed.
Measures.
The same measures as described earlier for the open field paradigm were
documented. These experiments were video-taped using the Cannon ZR850x camera to
ensure accurate recording of activity. The same researcher coded all the data.
Sample Size and Statistical Analysis
Based on experience of the Escayg lab, it was determined that 60 animals (20 in
each cohort—10 RH mutants and 10 WT mice) should be sufficient to provide enough
power to the analysis. After analysis, if statistical power was not reached, more animals
would be tested in future experiments. A two-way ANOVA statistical test was used to
examine differences between the groups. Tukey’s post-hoc analysis was also used.
Additionally, all data were assessed using the Grubb’s test for outliers as well as
descriptive statistics to obtain mean, standard deviation and standard error of the mean.
Each measure was analyzed separately. Additionally, a p < 0.05 was considered
statistically significant.

CHAPTER IV
RESULTS
Chapter four consists of the results of this descriptive, experimental study. Data
regarding the impact of stress on seizure phenotype and behavioral phenotype as well as
impact of an omega 3 PUFA as a neuroprotectant against abnormal neurological behavior
are reported.
RESULTS FROM AIM I
Purpose: To establish the picrotoxin-induced seizure phenotype of unrestrained as
well as restrained (stressed) R1648H (RH) mice compared to wild-type (WT)
littermates (both restrained and unrestrained).
Hypotheses: H1: RH mice will have increased frequency and duration as well as
severity of picrotoxin-induced seizure activity compared to WT mice, H2: Restraint stress
will increase the frequency and duration as well as worsen the severity of picrotoxininduced seizure activity in RH mice and WT mice compared to controls (RH and WT
unrestrained mice),
An experimental design of randomly selected RH mice and their wild-type (WT)
littermates experienced either restraint stress (n = 11 for each genotype) or unrestrained
conditions (n = 11 for RH mutants, and n = 10 for WT group). Total numbers in each
group varied slightly from the original goal of n = 12 in each group due to a few animals
63

64
having complete unresponsiveness to picrotoxin injections. Each group of mice were
examined at approximately post-natal day (PND) 90 and weighed on average 25grams.
There was no difference between the RH mice and their WT littermate’s reaction
to picrotoxin (5mg/kg) within the first five minutes of dosing. Baseline data for initial
reactivity to picrotoxin were compared in Scn1a R1648H mutants (restrained and
unrestrained) to WT littermates (both restrained and unrestrained). Both restrained and
unrestrained mice in the RH and WT mice had similar latency to freezing activity (see
Figure 9). This suggests that metabolism of picrotoxin occurred equally between the
strains.
Figure 9. No significant differences in mutants vs. WT in both restrained and
unrestrained groups within the first five minutes. One outlier was detected via Grubb’s
test in the RH no stress group and was removed from the final analysis.

Latency to Freezing/Staring
Picrotoxin (5 mg/kg)
5

Latency (min)

4

3

2

1

0
WT
(n=10,11)

R1648H Het
(n=10,11)

No Stress
Restraint Stress
- No Significant Differences
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Following the first few minutes of injection, RH mutants exhibit increased
myoclonic jerk frequency in unrestrained conditions. Compared to unstressed
(unrestrained) WT littermates, unstressed RH mutants had over four times the number of
myoclonic jerks per minute (Tukey’s test, p = 0.01, Table 2). There was no difference in
myoclonic jerk frequency between restrained groups. Nor was there a difference in
latencies to myoclonic jerk between all four groups. There was a trend towards a
significance difference among WT littermates between condition of unrestrained and
restrained (Tukey’s test, p = 0.052) for latency to myoclonic jerk; however, there was no
difference between condition among mutants (Tukey’s test, p = 0.142).
RH mutants and WT littermates experiencing restraint stress exhibit decreased
latencies to partial seizure onset. To determine the seizure phenotype of RH mutants
(restrained and unrestrained) compared to their WT littermates, latency to various levels
of seizures as well as seizure frequency were analyzed. ANOVA detected main effects of
restraint stress in regards to latency to focal seizures [F(1,38) = 9.317, p = 0.004], and
latency to bilateral forelimb clonus [F(1,39) = 12.094, p = 0.001]. While stressed RH
mutants had significantly decreased latencies to focal seizures (Tukey’s test, p = 0.005)
and to bilateral forelimb clonus (Tukey’s test, p = 0.012) compared to un-stressed
mutants, stressed WT littermates (versus un-stressed WT) only had decreased latency to
bilateral forelimb clonus (Tukey’s test, p = 0.028). There was no difference between
mutants and their WT littermates in regards to latencies to partial seizures (either stressed
or un-stressed) (Table 2). Surprisingly, there were no differences detected in partial
seizure frequency between RH mutants and WT littermates.
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RH mutants experiencing restraint stress exhibit decreased latencies in
generalized seizures compared to un-stressed RH mutants. Although there were no
differences in latency to generalized seizures noted between genotypes, ANOVA did
detect main effects of stress [F(1,39) = 8.719, p = 0.005]. Post-hoc analysis revealed that
RH mutants had significantly decreased latency to generalized seizure (Tukey’s test, p =
0.012, Table 2). Surprisingly, there was no main effect of genotype or condition or
interaction effect in regards to total number of generalized seizures or frequency of
generalized seizures (seizure/minute). However, a one-way ANOVA was performed to
more closely examine the frequency of generalized seizures between stressed RH mutants
and stressed WT group. Analysis detected a trend in significance between RH mutants
(6.5 ±1.6) and WT littermates in (2.8 ±1.6) regarding the number of generalized seizures
(F(1,20) = 4.20, p = 0.054).
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Table 2 Latencies and frequencies of various levels of seizure activity in RH
mutants and WT littermates receiving IP injections of picrotoxin (5mg/kg) and
observed for 60 minutes. Shown is the comparison of mean ± S.E. of latencies to
myoclonic jerk, focal seizure, bilateral forelimb clonus and generalized seizures as well
as frequency (seizure per minute) of myoclonic jerk, focal seizure, bilateral forelimb
clonus and generalized seizure in restrained and unrestrained RH mutants compared to
restrained and unrestrained WT mice. Shown is the mean ± S.E of the total number of
generalized seizures in all four groups. One outlier was detected via Grubb’s test in the
WT no stress group and the WT stress group and was removed from the final analysis for
latency to myoclonic jerk. One outlier was detected in the WT no stress group and was
removed from the final analysis for myoclonic jerk frequency. One outlier was detected
via Grubb’s test in the WT no stress group and was removed from the final analysis for
latency to focal seizures. One outlier was detected via Grubb’s test in the WT stress
group and was removed from the final analysis for generalized seizure frequency.
Unrestrained (un-stressed)

Latency to Myoclonic
Jerk (min)
Latency to Focal
Seizure (min)
Latency to Bilateral
Forelimb Clonus (min)
Latency to
Generalized Seizure
(min)
Myoclonic Jerk
Frequency (Jerk/Min)
Focal Seizure
Frequency (Sz/Min)
Bilateral Forelimb
Clonus Frequency
(Sz./min)
Generalized Seizure
Frequency (Sz./min)
Total Number of
Generalized Seizures

Restrained (stressed)

Scn1a R1648H

WT

Scn1a R1648H

WT

6.9 ±0.7

6.6 ±0.8

6.9 ±0.7

5.1 ±0.7

19.8 ±1.6

18.9 ±1.7

13.2 ±1.6 ª

15.7 ±1.6

27.1 ±3.3

28.3 ±3.4

14.9 ±3.3 ª

17.5 ±3.3 ª

35.9 ±5.1

39.8 ±5.4

16.9 ±5.1 ª

28.2 ±5.1

1.9 ±0.4 *

0.4 ±0.4

1.1 ±0.4

1.5 ±0.4 ᵇ

1.1 ±0.4

1.4 ±0.4

1.8 ±0.4

1.9 ±0.4

0.4 ±0.2

0.7 ±0.2

0.6 ±0.2

0.9 ±0.2

0.1 ±0.03

0.08 ±0.03

0.12 ±0.03

0.07 ±0.03

5.0 ±1.6

3.5 ±1.6

6.5 ±1.6

2.8 ±1.6

*p < 0.05, ANOVA followed by Tukey’s post-hoc test within condition between RH vs.
WT
ª p < 0.05, ANOVA followed by Tukey’s post-hoc test within genotype between
condition of restraint vs. unrestrained
ᵇ p = 0.052, ANOVA followed by Tukey’s post-hoc test within genotype
A

F(1,20) = 4.20, p = 0.054, one-way ANOVA, within condition between RH vs. WT

A
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Seizure severity does not differ between RH mutants and WT littermates. Both
restrained and unrestrained RH mutants and WT littermates were compared using twoway ANOVA with no main effect of genotype or condition detected as well as no
interaction effect noted in total seizure time (Figure 10). However, when we compared
each condition (stressed vs. un-stressed) within genotype using an independent t-test, we
found a trend for significance between RH stressed (26.6 ± 4.4) and RH un-stressed (16.9
± 2.9) (t (20) = -1.820, p = 0.084) in the total percentage of seizure time. When we
compared the RH mutants vs. WT group within condition of stressed (RH 16.921 ±
2.949, WT 25.848± 5.1, p = .138) as well as unstressed (RH 26.6 ± 4.4, WT 23.3 ± 3.4, p
= 0.56), there were no trends towards significance noted. Post-hoc power analysis
revealed a statistical power of 0.29 in regard to comparing RH stressed vs. RH unstressed animals due to insufficient animals in each group; therefore, ongoing
experiments will augment this sample size. No differences were detected in level reached
in the Racine seizure severity scale among the 4 groups (Figure 11). Additionally, none
of the groups differed in incidence of long-lasting clonus (status epilepticus) (p = 1.0).
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Figure 10.
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Figure 11.
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Results from Aim II
Purpose: To establish the behavioral response to stress using multiple behavior
experiments in the RH mice compared to WT mice.
Hypotheses: H3: The phenotypic behavioral traits in this model of GEFS+ will parallel
those traits seen in epileptic humans
Specific Aim I found that stress worsens the seizure response in RH animals;
therefore we sought to examine for deficits in response to behavioral paradigms which
are a natural stressor. A longitudinal design of randomly selected RH mice and their
wild-type (WT) littermates experienced a multitude of experiments (n = 12 for each
genotype) in order to examine the behavioral phenotypes. Each group of mice were
examined at approximately post-natal day (PND) 90 and weighed on average 25grams.
RH mutants exhibit an increased amount of locomotor activity compared to WT
littermates in the open field experiment. To perform a more detailed analysis of the
locomotor activity, multiple measures of total distance travelled and immobility were
obtained (Table 3). The RH group had a higher distance travelled in the edge zone when
compared with their WT littermates (t(21) = -2.787, p = 0.011). There was no difference in
total distance travelled in the center zone (p = 0.568) between groups. However, the RH
mutants exhibited increased total overall distance travelled (t(21) = -2.649, p = 0.015).
When analyzing the total time spent in both center and edge zones between RH mutants
and their WT littermates, there was no difference, and when the speed of both groups was
compared, the RH mutants displayed a faster average than the WT group (t(21) = -2.665, p
= 0.014). This higher speed resulted in the increased total average distance travelled.
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Conversely, the total time spent immobile (t(21) = 3.867, p < 0.001), and the total number
of immobile episodes (t(21) = 3.554, p = 0.002) was lower in the RH group. Sufficient
power was obtained with alpha > 0.9. Additionally, not only was the RH group less
immobile than the WT group, the RH group trended toward significance in that it took
longer to have their first immobile episode (t(22) = -2.066, p = 0.051).
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Table 3 Total locomotor activity measures in RH mutants and WT
littermates experiencing the Open Field test. Shown is the comparison of mean ± S.E.
of the total distance travelled, average speed, immobility measures (total time, number of
episodes, latency), center measures (total time, number of entries, total distance), edge
measures (total distance, total time), and fecal boli. One outlier was detected via Grubb’s
test in the WT group and was removed from the final analysis for total distance travelled,
average speed, edge zone distance travelled, and latency to enter center. One outlier was
detected via Grubb’s test in the RH group and was removed from the final analysis for
total time immobile, and latency to enter center.
Scn1a R1648H

WT

88.9 ±4.2 *

73.3 ±4.1

Average Speed (cm/sec)

9.9

8.2 ±0.5

Total Time Immobile (sec)

107.6

±6.4 ª

172.8 ±14.9

Number of Immobile Episodes

27.9

±2.1 *

40.2 ±2.7

Total Distance Travelled (meters)

±0.5*

Latency to Immobility (sec)

58.4 ±10.5 ᵇ

31.1 ±7.9

Total Time in Center Zone (sec)

62.3 ±10.6

52.1

Number of Entries to Center Zone

42.5 ±5.6

38.4 ±4.2

Total Distance Travelled in Center Zone

9.1 ±1.2

8.2 ±0.9

79.8 ±3.7 *

65.6 ±3.5

Total Time in Edge Zone (sec)

837.3 ±10.7

847.3 ±4.5

Number of Fecal Boli

1.3 ±0.5

1.0 ±0.4

±4.4

(meters)
Total Distance Travelled in Edge Zone
(meters)

*p < 0.05, t-test, RH mutant vs. WT

ª p < 0.001, t-test, RH mutant vs. WT
ᵇ p = 0.051 t-test, RH mutants vs. WT
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RH mutants do not demonstrate signs of anxiety-like behavior in the open field
test compared to WT littermates. Measures of anxiety in the open field test include time
spent in the center of the field as well as the number of fecal boli defecated by the animal.
None of the center measures (total time, total distance, number of entries) were different
between the RH group and the WT group (Table 3). Additionally, the number of fecal
boli was similar between both groups.
RH mutants do not demonstrate signs of depressive-like behavior in the forcedswim test compared to WT littermates. The forced-swim test is a well-known measure of
depressive-like behavior or despair (Holmes, 2003). Figure 12 shows the comparison of
total time immobile (indicated by floating) between the RH and WT groups for the total
10 minutes of the test. There were no significant differences in either the total time
immobile or the latency to first immobile episode when comparing both groups.
Figure 12 Total time immobile (seconds) in RH and WT groups.
Total Immobility (Forced Swim Test)
250

Immobility (s)
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0
Wildtype
(n=12)
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- No Significant Differences
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There was a trend for significance to higher total struggling time (sec.) in the RH mutants
(35.49 ± 8.45) compared to WT littermates (16 ± 5.23) (t(21) = -1.920, p = 0.069);
however, struggling activity is not indicative of depressive-like behavior. One outlier
was detected via Grubb’s test in the WT group and was removed from the final analysis
for total time struggling.
RH mutants show no difference in exploratory behavior in the novel cage
environment test compared to WT littermates. When comparing the RH mutants with the
WT group, the only significant difference found was that the RH animals displayed a
decreased number of immobile episodes (42.00 ± 3.88) compared to WT (55.33 ± 4.38,
t(21) = 2.263, p = 0.034); however, the total time spent immobile was not different
between groups (p = 0.752). Power analysis for total time spent immobile was less than
desired, therefore we may not have been able to detect a difference in this variable. Table
4 describes the variables examined in the paradigm with the RH mutants and their WT
littermates for the total 15 minutes of time spent in the novel cage.
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Table 4 Total exploratory activity measures in Scn1a R1648H mutants and
WT littermates experiencing the Novel Cage Environment paradigm. Shown is the
comparison of mean ± S.E. of the total number of stretch-attends, grooming measures
(frequency, duration, latency), rearing, burrowing measures (frequency, duration,
latency), immobility measures (total time, number of episodes), and fecal boli. One
outlier was detected via Grubb’s test in the RH group and was removed from the final
analysis for number of grooming episodes, total time grooming, number of immobile
episodes, and total time immobile.
Scn1a R1648H

WT

Total Number of Stretch-Attends

0.50 ± 0.29

0.75 ± 0.58

Total Number of Grooming Episodes

16.46 ± 2.99

14.33 ± 1.86

Grooming Duration (sec.)

18.93 ± 2.74

16.57 ± 1.95

Grooming Latency (sec.)

64.74 ± 15.38

70.78 ±13.24

Total Number of Rearing Episodes

122.75 ± 7.75

119.08 ± 7.16

Total Number of Burrowing Episodes

78.91 ± 8.16

76.08 ± 6.23

Burrowing Duration (sec.)

71.93 ± 9.55

71.62 ± 6.52

Burrowing Latency (sec.)

135.21 ± 18.97

158.80 ± 17.22

Total Time Immobile (sec.)

68.01 ± 6.77

65.28 ± 5.33

Total Number of Immobile Episodes

42.00 ± 3.88 *

55.33 ± 4.38

Total Fecal Boli

2.08 ± 0.43 ª

3.59 ± 0.59

*p < 0.05, t-test, RH mutant vs. WT
ª p = 0.054 t-test, RH mutants vs. WT

RH and their WT littermates do not have preference for any zone of the Social
Interaction test box. Baseline activity in each zone of the Social Interaction test box was
demonstrated that there was no preference for any zone prior to the addition of a stranger
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mouse. No differences were found for either the RH mutants or their WT littermates
(Figure 13).
Figure 13
Empty Box Measures
WT Means
Het Means

Time Spent in Each Chamber (s)
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RH mutants as well as their WT littermates express sociability behavior in the
Social Interaction paradigm. Repeated measures ANOVA revealed a main effect of
stranger presence (F(1,22) = 18.248, p < 0.001, statistical power = 0.986). Post-hoc
analysis found that the RH mutants spent nearly 70% more time (Tukey’s test, p = 0.027)
and the WT group spent over 50% more time (Tukey’s test, p = 0.001) in the large area
that housed the stranger mouse (Figure 14) when compared with the empty area.
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Figure 14
Sociability (Stage 2) - Large Zone-Total Time
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Interestingly, the number of entries into this large zone containing the stranger mouse
was not different between groups or within genotype (Figure 15).
Figure 15
Sociability (Stage 2) - Large Zone-Number of Entries
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To more closely examine the interaction with the new stranger mouse, we analyzed the
time spent with the new stranger mouse in a much smaller area surrounding the stranger.
Repeated measures ANOVA detected a main effect of stranger presence (F(1,22) = 9.45, p
= 0.006, statistical power > 0.8) on the number of entries in the smaller zone; however,
post-hoc analysis revealed a significant difference for only the WT group with condition
(empty 12.33 ± 1.33, stranger side 22.50 ± 1.93, p = 0.008). ANOVA also detected a
main effect of stranger presence on the total time spent with the stranger in the small zone
(F(1,22) = 27.920, p < 0.001, statistical power > 0.9). Similar to time spent with the
stranger mouse in the large zone, post-hoc analysis of the small zone revealed significant
differences for both RH mutants and their WT littermates in regards to time spent with
the stranger mouse versus the empty side (Figure 16).
Figure 16
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RH mutants express preference for social novelty in the Social Interaction
paradigm. Although there was no difference among genotypes in the number of entries
into the large zone containing the novel stranger mouse versus the older stranger mouse
(Figure 17), there were significant differences detected in the total time spent with the
novel mouse (Figure 18) with ANOVA detecting a significant interaction effect (F(1,22) =
5.009, p = 0.036) of genotype and stranger presence. Post-hoc analysis revealed that
there was no difference in the WT group’s interaction with the novel mouse compared to
the older stranger mouse (p = 0.252); however there was a trend for significant difference
within the RH group (Tukey’s test, time with old mouse 169.52 ± 16.70 sec. vs. time with
novel mouse 222.82 ± 14.61, p = 0.06). Additionally, post-hoc analysis detected a
significant difference between genotypes for the amount of time spent with the novel
stranger (Tukey’s test, p = 0.042) (Figure 18). Interestingly, there was a trend for
significant difference with total time spent with the older stranger mouse between the RH
mutants (169.52 ± 16.70 sec.) and their WT littermates (209.85 ± 11.71 sec., p = 0.063)
(Figure 18).
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Figure 17
Social Novelty (Stage 3) - Large Zone - Number of Entries
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Figure 18
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Again, to more closely examine the interaction of both groups with the novel stranger
mouse compared to the older, more familiar stranger mouse, we analyzed the total time
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and number of entries in a much smaller zone surrounding the stranger mice. Repeated
measures ANOVA detected an interaction effect of genotype and stranger presence in the
number of entries into the small zone housing the novel stranger mouse compared with
the small zone housing the older stranger mouse (F(1,22) = 7.18, p = 0.014) (Figure 19).
Figure 19
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Post-hoc analysis revealed that not only was there a significant increase in the number of
entries into the small zone containing the novel mouse compared to the small zone
containing the older mouse for the RH mutants (Tukey’s test, 24.16 ± 2.64 vs. 14.91 ±
2.80 respectively, p = 0.021), but the RH mutants had a significantly higher number of
entries into the small zone of the novel stranger (24.16 ± 2.64) when compared to the WT
group (14.66 ± 1.76, p = 0.006). In addition to the number of entries into the small zone
housing the stranger mice, we examined the total time spent in these zones for each
genotype (Figure 20). Repeated measures ANOVA revealed a significant interaction
effect of genotype and stranger presence (F(1,22) = 4.969, p = 0.036). Although there was
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no significant difference detected within the WT group, the RH mutants spent over 40%
more time with the novel mouse compared to time spent with the older stranger mouse
(126.87 ± 12.37 sec. vs. 88.10 ± 10.33 respectively, p = 0.043, Tukey’s test) (Figure 20).
Interestingly, the RH mutants spent less time with the older stranger mouse (88.10 ±
10.33 sec.) compared to the WT group (119.88 ± 9.46, p = 0.046, Tukey’s test).
Figure 20
Social Novelty (Stage 3) - Small Zone - Total Time
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RH mutants express hyperactive behavior compared to their WT littermates in the
Social Interaction paradigm. We also examined the total activity of both genotypes and
found that the RH mutants travelled a significantly longer distance than the WT group
(120.09 ± 8.55 vs. 95.27 ± 4.67 meters respectively, t (22) = -2.547, p = 0.018).
Additionally, the RH group travelled at a faster speed than their WT littermates (20.0 ±
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1.42 cm/sec vs. 15.87 ± 0.77 cm/sec., t (22) = -2.545, p = 0.018). Lastly, the immobility in
the RH mutants was diminished by 50% compared to the WT group (t (22) = 3.524, p =
0.002) (Figure 21).
Figure 21
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RH mutants and their WT littermates exhibit fear response in the presence of a
predator odor. One way to assess the potential fear response of a rodent is to observe the
freezing behavior during presence of a predator odor compared to the freezing response
before and after the presence of the odor. Repeated measures ANOVA detected a main
effect of genotype (F(1,18) = 6.381, p = 0.021) as well as a main effect of presence of odor
(F(2,36) = 44.201, p < 0.001) on the number of freezing episodes; however, there was no
significant interaction effect found (p = .201). Through post-hoc analysis, baseline data
for day one of the predator odor experiment (before odor) revealed no significant
difference in the number of freezing episodes between the RH group and their WT
littermates (Tukey’s test, p = 0.35) (Figure 22). And while there was a significant
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increase within genotype for the number of freezing episodes between all conditions (p <
0.05 for all conditions within genotype), there was significantly fewer number of freezing
episodes between the RH mutants and WT group in day three of the experiment (presence
of odor) (61.40 ± 10.30 vs. 103.50 ± 11.65 respectively, p = 0.016, Tukey’s test) and in
day 5 of the experiment (after odor) (92.50 ± 12.98 vs. 136.20 ± 17.81, p = 0.013,
Tukey’s test) (Figure 22).
Figure 22
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We also analyzed the total amount of time spent freezing in the before odor,
during odor and after odor conditions for both the RH mutants and the WT group. There
was a significant main effect of genotype (F(1,17) = 5.112, p = 0.037) and condition (F(2,34)
= 23.871, p < 0.001); however there was no interaction effect (F(2,34) = 2.845, p = 0.072)
(Figure 23). Through post-hoc analysis, it appears that there is no significant difference

85
between the RH mutants and WT group in total freezing time within the first day of the
paradigm (before odor). There is over 1.5 times less freezing in the mutants compared to
the WT group on day 3 (odor) (54.68 ± 12.41 vs. 93.667 ± 12.708 respectively);
however there is only a trend for significance between these data (p = 0.064, Tukey’s
test). On day 5 (after odor), the RH mutants and WT group do differ significantly (79.47
± 13.70 vs. 139.233 ± 27.907 respectively, p = 0.006, Tukey’s test) (Figure 23). It was
also noted that the WT group had significantly increased total freezing time between all
conditions of before odor, odor, and after odor (p < 0.05 between all conditions).
Interestingly, despite having a significantly increased number of freezing episodes
between all conditions, the RH mutants did not have increased total freezing time
between day 1 (before odor) and day 3 (odor) (24.85 ± 3.41 vs. 54.68 ± 12.41
respectively, p = 0.186, Tukey’s test). Nor did the RH group have significantly
increased freezing time between day 3 (odor) and day 5 (after odor) (54.68 ± 12.41 vs.
79.47 ± 13.70 respectively, p = 0.307, Tukey’s test). Post-hoc analysis did reveal a
significant increase in total freezing time for the RH mutants from day 1 (before odor)
compared to day 5 (after odor) (24.85 ± 3.41 vs. 79.47 ± 13.70, p = 0.007, Tukey’s test).
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Figure 23
One outlier was detected via Grubb’s test in the RH group and was removed from the
final analysis for total freezing time.
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RH mutants and their WT littermates exhibit anxiety-like behavior in the Predator
Odor paradigm. Anxiety-like behavior can potentially be interpreted when in a decrease
in normal exploratory behavior in a rodent (Holmes, 2003). The exploratory activity of
rearing was observed and analyzed with repeated measures ANOVA and found that while
there was no significant main effect of genotype (p = 0.204), there was a significant main
effect of the condition of odor presence (F(2,34) = 61.944, p < 0.001, statistical power >
0.9). No interaction effect was found (F(2,34) = 1.006, p = 0.376). We examined the
number of times the animals displayed rearing activity and found a significantly
decreased number of rears within both the RH mutants (198 ± 13.116 vs. 144.0 ± 12.70,
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p < 0.001) and the WT group (185.70 ± 10.35 vs. 113.70 ± 8.98, p < 0.001) from before
odor to the presence of odor (Figure 24). And while both RH mutants and their WT
littermates had significantly decreased number of rears from the condition of before odor
to after odor as well (both p < 0.001), there was no significant difference for either
genotype in the number of rears from odor presence to after odor presence (both groups p
> 0.05) (Figure 24). Interestingly, there was only a trend for significant difference
between genotypes during odor presence between the RH mutants (144.0 ± 12.70) and
the WT group (113.70 ± 8.98, p = 0.071, Tukey’s test) (Figure 24). There were no
significant differences noted in the number of fecal boli from either group between or
within any condition.
Figure 24 One outlier was detected via Grubb’s test in the WT group and was removed
from the final analysis for total number of rearing episodes.
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Results from Aim III
Purpose: Determine the neuroprotective effects of subcutaneous injections of
docosahexaenoic acid (an omega 3 PUFA) on hyperactive behavior in RH mice.
Hypothesis: H4: Administration of omega 3 PUFA’s to the Scn1aR1648H mice will lead to
a reduction in perturbed behavioral traits
Because Specific Aim II noted clear and consistent evidence of hyperactive
behavior, a longitudinal design of randomly selected RH mice and their wild-type (WT)
littermates experienced SQ injections of either DHA 100mg/kg or vehicle (oleic acid
100mg/kg) or no injections. Each group of mice were examined at approximately postnatal day (PND) 35 and weighed on average 18 grams. The initial goal for the number of
animals in this experiment was 10 in each group for a total of 60 animals. Because of the
number of animals born in each litter, randomization to each group, and animal morbidity
during experimentation, we ended up with WT unhandled controls (n = 17), WT with
DHA injections (n = 12), WT with OA injections (n = 12), RH unhandled controls (n =
14), RH with DHA injections (n = 10), and RH with OA injections (n = 10).
RH mutants and their WT littermates receiving DHA (100mg/kg) SQ or Oleic
Acid (100mg/kg) daily for two weeks starting at weaning had reduced locomotor activity
compared to unhandled controls. Two-way ANOVA detected a significant main effect
of genotype (F(1,69) = 10.27, p = 0.002, statistical power > 0.8) and condition (F(2,69) =
19.45, p < 0.001, statistical power > 0.8) with no interaction effect regarding the total
distance travelled in the open field paradigm (see Table 5). Tukey’s post-hoc analysis
revealed that RH mutants receiving either DHA or OA had reduced distance travelled
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compared with RH unhandled controls (p < 0.01). Tukey’s post-hoc analysis also
revealed that WT’s receiving either DHA or OA had reduced distance travelled compared
with WT unhandled controls (p < 0.01). RH mutants receiving DHA travelled a farther
distance than WT’s receiving DHA (p = 0.028). Additionally, there was a trend for
significance difference for unhandled RH mutants travelling farther than unhandled WT
(p = 0.054). Interestingly, there was no difference in the OA group for RH vs. WT (p =
0.174).
Two-way ANOVA also detected a significant main effect of genotype (F(1,69) =
10.22, p = 0.002, statistical power > 0.8) and condition (F(2,69) = 19.49, p < 0.001,
statistical power > 0.8) with no interaction effect regarding the average speed in the open
field paradigm (see Table 5). Tukey’s post-hoc analysis revealed that RH mutants
receiving either DHA or OA travelled at a slower speed compared to the RH unhandled
controls (p < 0.01). Tukey’s post-hoc analysis also revealed that WT’s receiving either
DHA or OA travelled at a slower speed compared to the WT unhandled controls (p <
0.01). RH mutants receiving DHA travelled faster than WT receiving DHA (p < 0.05),
and there was a trend for significance for RH unhandled controls travelling faster than
WT unhandled controls (p = 0.054).
Two-way ANOVA also detected a significant main effect of genotype (F(1,68) =
14.02, p < 0.001, statistical power > 0.8) and condition (F(2,68) = 19.17, p < 0.001,
statistical power > 0.8) with no interaction effect regarding the total time immobile in the
open field paradigm (see Table 5). Tukey’s post-hoc analysis revealed that RH mutants
receiving OA had increased immobility compared to the RH unhandled controls (p <
0.01). There was a trend for significance for RH mutants receiving DHA to have
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increased immobility compared to RH unhandled controls (p = 0.078). Tukey’s post-hoc
analysis also revealed that WT’s receiving either DHA or OA had increased immobility
compared to the WT unhandled controls (p < 0.01). RH mutants receiving DHA had
reduced immobility compared to WT receiving DHA (p = 0.002), and there was a trend
for significance for RH receiving OA to have reduced immobility compared to WT
receiving OA (p = 0.084). RH unhandled controls did not differ from WT unhandled
controls in total time immobile (p = 0.201). Conversely, RH unhandled controls did have
reduced number of immobile episodes compared to WT unhandled controls (p = 0.048).
Two-way ANOVA also detected a significant main effect of genotype (F(1,67) = 8.417, p
= 0.005, statistical power = 0.777) and condition (F(2,67) = 2.45, p < 0.001, statistical
power > 0.8) with no interaction effect regarding the total number of immobile episodes
in the open field paradigm (see Table 5). Tukey’s post-hoc analysis revealed that RH
mutants receiving DHA or OA had increased number of immobile episodes compared to
the RH unhandled controls (p < 0.01). Tukey’s also revealed that WT’s receiving DHA
or OA had increased number of immobile episodes compared to WT unhandled controls
(p < 0.01).
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Table 5 Total locomotor activity measures in RH mutants and WT littermates
experiencing the Open Field test during the omega 3 Trial. Shown is the comparison
of mean ± S.E. of the total distance travelled, average speed, immobility measures (total
time, number of episodes). One outlier was detected via Grubb’s test in the WT group
(unhandled) and was removed from the final analysis for total time immobile and number
of immobile episodes. One outlier was detected via Grubb’s test in the WT group (OA)
and was removed from the final analysis for total number of immobile episodes.

Unhandled Controls

RH
Total Distance
Travelled (m)

72.94 ±
4.39

WT

DHA

RH

OA

WT

RH

WT

63.62 ±
3.82

54.77 ±
2.88 * b

42.09 ±
3.12 *

53.33 ±
4.21 *

45.59 ±
2.55 *

Average Speed
(m/sec)

0.086 ±
0.0052 a

0.075±
0.004

0.065 ±
0.003 * b

0.05
± 0.0037 *

0.063 ±
0.005 *

0.054
± 0.003
*

Total Time
Immobile (sec)

123.47 ±
15.96 a

157.78 ±
14.90

189.7 ±
24.75 b +

293.22
± 25.75 *

225.35 ±
23.82 *

279.83
± 22.18
*

25.64 ±
2.43 b

31.81 ±
2.11

47.16 ±
1.87 *

43.00 ±
3.16 *

45.36 ±
1.73 *

Total Number of
Immobile Episodes

38.40 ±
3.06 * b

* p < 0.01 within genotype compared to Control
b
+

a

p < 0.05 within condition Het vs. WT
p = 0.078 trend within genotype compared to Control
p = 0.054 within condition Het vs. WT

In this chapter, the results of a descriptive, experimental study were presented to
illustrate findings using an animal model of GEFS+. The picrotoxin-induced seizure
phenotype of unrestrained as well as restrained (stressed) animals was described.
Additionally, the behavioral phenotypes using multiple experimental paradigms (open
field test, forced swim test, novel cage environment test, social interaction test, and
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predator odor test) were explored and described. Lastly, the impact of DHA, an Omega 3
PUFA, after weaning as neuroprotection for the RH mouse against hyperactivity was also
presented.

CHAPTER V
DISCUSSION
Chapter five presents a discussion of the study results and provides insight for
nursing practice. This chapter will also discuss the strengths and limitations of the study.
Study conclusions will provide future recommendations for research. This study reports
that stress worsens the seizure phenotype in animals with an Scn1a mutation
recapitulating GEFS+. This study is also the first to report hyperactive locomotor
behavior in a mouse model of GEFS+. Better understanding of seizure and behavioral
phenotypes in this disorder will help to guide improved treatment and prevention of the
primary disease as well as co-morbid conditions.
Stress is reported to increase the severity and frequency of seizure activity
(Bosnjak et al., 2002; Forcelli et al., 2007; Swinkels et al., 1998); however, there is still a
scarcity of information regarding GEFS+ and the impact of stressful events.
Additionally, the seizure phenotype of GEFS+ is reported as having a high degree of
seizure variability (Mahoney et al., 2009), and information regarding specific behaviors
such as depression and anxiety is lacking. There is an even greater lack of knowledge in
the effects of omega 3 PUFA’s in regards to neurological deficits in those with epilepsy.
This study adds to the body of knowledge of seizure and behavioral phenotypes of
persons with GEFS+ as well as the impact of omega 3 PUFA’s on neurological deficits.
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Seizure Phenotype in Stressed and Unstressed RH Mutants and WT Littermates
The first aim of this study was to describe the picrotoxin-induced seizure
phenotype in stressed and unstressed animals with the RH mutation. Using restraint
stress on male animals approximately 90 days old we noted differences in seizure
phenotype between RH mutants and their WT littermates, and that the stressful
experience impacted the seizure phenotype in both groups.
In any experimental paradigm, it is import to ensure the validity of results through
rigorous control of independent variables. A mouse can experience stress during simple
handling and housing (Longordo, Fan, Steimer, Kopp, & Lthi, 2011). Because the effects
of restraint stress on seizure phenotype were explored, the experimental protocol used
every effort to reduced extraneous stressful events. The animals were single-housed and
maintained in standard housing with water and rodent chow available ad libitum one
week prior to all testing. Additionally, all tests were performed in the morning between
the hours of 0900 and 1200. This helped to maintain consistency and control for any
hormonal or circadian changes (Moura, Gimenes-Jnior, Valentinuzzi, & Xavier, 2009;
Roedel, Storch, Holsboer, & Ohl, 2006). During experimentation, the room was quiet
and controlled for environmental conditions that may induce stress such as temperature
and light changes (Bailey & Crawley, 2009). On the morning of the test, the animals
were moved to the experimental room two hours prior to testing to allow for acclimation
to the new environment and cage movement. For the behavioral paradigms, a variety of
tests were used to determine if a behavior was observed in multiple experiments. Any
behavior that was able to be scored using computerized software was done so, and all
other behaviors were scored by the same researcher.
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The baseline data for initial responsivity to picrotoxin are important to note
because this demonstrates that mice in all four groups had the same initial reaction time
to picrotoxin. This allows for future comparisons of seizure latency and activity and
indicates that picrotoxin is metabolized equally among all the groups. If the mutants had
initially responded earlier or later than their WT littermates, comparisons of other
latencies would be difficult.
The results of increased seizure activity under stressful conditions in this model of
GEFS+ are similar with reports of elevated seizure activity associated with stress in other
epileptic disorders (Bosnjak et al., 2002; Forcelli et al., 2007; Swinkels et al., 1998). One
reason for this could be because corticosterone is released during a stressful event and
affects the function of voltage-gated ion channels (Brunson et al., 2002; de Kloet et al.,
2005). Obtaining serum corticosterone levels would be important for comparison in the
stressed and un-stressed animals and should be collected in future studies using this
model. Both the RH mutants and the WT group had worse seizure phenotypes in
response to stress; however, it appears as if restrained (thus stressed) RH mutants have a
stronger reaction. This study helps to validate that a genetically engineered mouse model
of a human disease shows many of the same traits found in humans with similar
conditions. Through this study, we have now provided evidence for strategies to help
reduce morbidity of disease as well as address complaints found in humans.
Picrotoxin, used to induce epileptogenesis in this study, blocks GABAA receptors
(Hill, Simmonds, & Straughan, 1972). Because the R1648H as well as other missense
mutations on the SCN1A gene are reported to cause reduced inhibition of GABAergic
interneurons (Hawkins et al., 2011; Martin et al., 2010; Ohno et al., 2010), picrotoxin
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should be effective in inducing increased seizure activity in animals with this genetic
mutation compared to animals without this mutation. However, few researchers have
used this agent for epileptogenesis in experimental paradigms involving animals with
sodium channel mutations. The Escayg lab reports using kainic acid (Martin et al., 2010;
Tang et al., 2009) or flurothyl (Martin et al., 2010) to examine induced seizure activity in
animals with this particular mutation. Perhaps using another pro-convulsant that acts on
GABA receptors would be useful in determining if similar results would be found.
Behavioral Phenotype in RH Mutants and WT Littermates
The second aim of this study was to examine the behavioral phenotypes in mice
with the RH mutation. RH mutants underwent various behavioral paradigms to elucidate
differing behaviors, if any, from their WT littermates. Through multiple paradigms, a
clear and consistent evidence of hyperactive behavior exhibited by the RH mutants was
found.
Hyperactivity
In both the open field and social interaction paradigms, the adult mutants travelled
a greater distance and exhibited less immobility. Additionally, their speed was
significantly greater. These data were also found in ‘adolescent’ animals (PND 35 is
considered adolescence in mice). In the forced-swim test, the trend for increased
struggling behavior in the RH mutants may also be due to hyperactivity. Hyperactive
behavior and sodium channel mutations has rarely been examined, although multiple
studies have associated childhood epilepsy with ADHD (Cohen et al., 2012; Ottman et
al., 2011; Russ et al., 2012). Brunklaus and colleagues (2011) did report that in 163
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children with Dravet syndrome (the severe end of the GEFS+ spectrum of disorders)
there was a 66% prevalence of hyperactive behavior which is starkly contrasted with the
average national prevalence of ADHD of 8% (Bloom et al., 2009). The only other
evidence is found in a case report of a child with extended spectrum GEFS+ which is
considered more on the severe end of the spectrum of GEFS+ (Grant & Vazquez, 2005).
The current study’s novel finding of hyperactivity in an animal model of GEFS+ will
help inform the medical community of further assessment needed for individuals with
GEFS+.
Gamma (γ)-aminobutyric acid (GABA) is the main inhibitory neurotransmitter in
the brain and is released as needed to inhibit pyramidal neurons (excitatory), other
neurons that influence pyramidal neurons, or other GABAergic neurons (Tamminga et
al., 2004) and is believed to be play a part in the reduced inhibitory control seen in
ADHD. Because the prefrontal cortex (PFC) is considered to be the main area of the
brain responsible for control of behaviors that are altered in ADHD (Brennan & Arnsten,
2008), several animal studies have examined the alterations in locomotor activity when
GABA is either suppressed (increasing locomotor activity) or increased (reversal of
hyperactive behavior) in this region (Del Arco et al., 2011; Enomoto et al., 2011;
Lecourtier et al., 2010). A human study examined the GABA concentration in the brains
of children age 8-12 year-olds with confirmed diagnosis of ADHD (n = 13) and found
reduced concentrations when compared with matched healthy controls (n = 19) (Edden,
Crocetti, Zhu, Gilbert, & Mostofsky, 2012). The R1648H missense mutation on the
SCN1A gene specifically alters GABAergic interneurons (Martin et al., 2010); therefore
we infer that GABAergic interneurons in the PFC are also impacted which may explain
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the consistent evidence of increased locomotor activity found in the current study. This
is a novel finding. Children with GEFS+ experience a variety of other physiological
problems such as learning deficits, behavioral problems, neuropsychiatric disorders and
developmental delay (Mahoney et al., 2009); however hyperactive behavior associated
with GEFS+ (except in more severe cases) is not reported in the literature. It could be
that this has not been an area of focus or that larger, epidemiological studies have not
been conducted to assess other physiological or neurological deficits in this population.
The novel finding of hyperactivity in the current study will help to guide future studies to
specifically assess this behavior in persons with GEFS+. This is a critical component of
assessment because hyperactivity (as well as inattention) is a strong predictor of poor
health-related quality of life (Brunklaus et al., 2011).
Anxiety, Depression, Social Isolation
In the current study, none of the measures of anxiety-like behaviors revealed any
differences. However, it is important to note that decreased distanced travelled and
decreased speed in rodents may also indicate fear/anxiety (Holmes, 2003). Because the
RH mutants in this study exhibited an increased level of locomotor activity in regards to
distance travelled, speed of travel and time spent freezing, we speculate that these
animals might indeed have anxiety-like behavior. Within the novel cage paradigm, the
typical levels of anxiety (grooming, burrowing, and rearing) were not different between
groups; however, we speculate that a mouse exhibiting hyperactive locomotion may also
potentially display other increased activities such as rearing. Because the RH mutants’
baseline locomotor activity level is ‘hyperactive’, we might expect increased levels of
activity in their grooming, burrowing and rearing behavior. We found that these
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exploratory behaviors were similar between RH mutants and their WT littermates
suggesting that these exploratory behaviors were indeed reduced in the RH mutants due
to baseline differences compared to the WT group. It would be important to use other
experimental paradigms to measure anxiety that do not rely on locomotor activity
(Holmes, 2003) such as the startle response test (Curzon, Zhang, Radek, & Fox 2009).
The RH mutants in the current study did not exhibit any differences in floating
behavior compared to their WT littermates, suggesting a lack of depressive behavior
associated with this particular mutation. However, there was a trend for significance of
increased struggling behavior in the RH mutants (p = 0.069). We speculate that this
could also be a manifestation of hyperactive locomotor activity.
Social interaction was assessed using a paradigm that examined sociability as well
as preference for social novelty. Mice are typically social animals and prefer to explore
new animals within their environment (Bailey & Crawley, 2009). Both the RH mutants
and their WT littermates in the current study displayed sociability, meaning that they
explored a new animal introduced into their environment. Interestingly, the RH mutants
also displayed preference for social novelty, which means that when a second new animal
(10 minutes after the first new animal was introduced) was placed into their environment,
they preferred to explore the newest animal; however, their WT littermates did not have
preference for social novelty. The lack of preference for social novelty could be due to
the specific breed of mouse used in this study. C57BL/6J mice were reported to lack
preference for social novelty in the three chamber social box test when they either
encountered their own strain or another strain of mouse (Pearson, Defensor, Blanchard, &
Blanchard, 2010). The fact that the RH mutants did show preference for social novelty,
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even though they are C57BL/6J strain, indicates that possibly the Scn1a mutation
somehow enhanced this preference. It is important to note that during the experimental
paradigm, the test mouse was not removed and replaced in the center of the three
chambered box when each stranger mouse was introduced which could have altered the
time spent in any of the chambers depending in which chamber the test mouse was
standing. Future studies will include repeating this paradigm and removing the test
mouse during each phase of the experiment to ensure they are starting each phase in the
center of the test box.
Conditioned Memory
Both RH mutants and their WT littermates exhibited significantly more freezing
and reduced rearing frequencies when they were faced with predator odor compared to
the first episode of no odor. However, they continued to exhibit increased freezing and
reduced rearing when placed in the same type of container without the predator odor for
the second time. This may represent conditioned memory of fear for the odor in these
mice. It could be that this breed of mouse has a general affinity for conditioned fear
response. C57BL/6J mice experienced conditioned fear response when experiencing
cues (either auditory and/or footshock) and contextual changes (new environment
associated with the cues) (André, Cordero, & Gould, 2012; Paylor, Tracy, Wehner, &
Rudy, 1994). Therefore we are suggesting the findings in the current study may be due to
animal strain.
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Implications for SCN1A
The model used in the current study used a missense mutation on the Scn1a gene.
As stated earlier, SCN1A dysfunction mainly impacts GABAergic interneurons (Martin
et al., 2010). Dysfunction in GABAergic interneurons is also associated with
schizophrenia and autism (Chattopadhyaya & Di Cristo, 2012). Findings from this study
may extend beyond GEFS+ in that we may also be able to apply the findings to other
disorders with SCN1A or known GABAergic dysfunction. In addition, it may be that
genetic variants affecting SCN1A, but not necessarily in epilepsy, may contribute to
hyperactivity. This could mean that SCN1A is a candidate gene for hyperactivity. Han
and associates report hyperactivity in their Scn1a knock-out mouse (Han et al., 2012)
which further implicates SCN1A and GABAergic dysfunction in hyperactive behavior.
Neuroprotection Using DHA
Lastly, we wanted to determine if the daily administration of DHA, an omega 3
polyunsaturated fatty acid (PUFA), could provide neuroprotection to the RH mouse
against the deficits that we found in the behavioral paradigms. Results show that
subcutaneous injection of DHA 100mg/kg daily for two weeks after weaning [this time
period corresponds to adolescence in humans (Crawley, 2000)] did not significantly alter
locomotor hyperactivity in RH mutants compared to controls receiving injection of oleic
acid 100mg/kg. The reason for the lack of effectiveness could be due to multiple factors.
First, the optimal effective dose of DHA is not understood and varies greatly in human
studies (Bloch & Qawasmi, 2011; Ortega, Rodríguez-Rodríguez, & López-Sobaler,
2012). The dose of 100mg/kg was chosen based on the desire to avoid local injection site
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irritation but hopefully provide enough DHA to confer neuroprotection. Future studies
will use various doses, correlated with serum and brain levels, to assess efficacy against
hyperactive locomotion. Second, the length of time of administration may have been
inadequate. Future studies will also use longer time periods before assessing levels of
locomotor activity. We noted that RH and WT controls injected with vehicle (oleic acid)
had reduced levels of activity similar to the RH mutants and WT’s injected with DHA
respectively. Additionally, animals in both groups (injected either with DHA or OA) had
similar improvements in their deficits compared to the unhandled controls within the
same genotype. The act of daily injections involves a certain amount of handling of the
animals which could have led to the animals becoming accustomed to a new or stressful
(such as that of being placed in an open field) event thereby reducing locomotion by
reducing fear. This is only a postulation because we do not know if the animals exhibit
increased locomotor activity because of innate hyperactivity or because of anxiety in
stressful situations.
Implications for Nursing Practice
The main goal of nursing care is to reduce and prevent disease morbidity, and
knowledge gained from the current study will guide clinical nursing practice as well as
nursing research. Nurses assess patients with epilepsy in a variety of settings including
hospitals, outpatient clinics, and community settings (health setting as well as home
setting). As nurses constitute the largest group of healthcare providers in the United
States, our time spent with patients in assessing and evaluating outcomes can guide the
direction of care. Providing evidence-based nursing practice helps to ensure that quality
patient care is received (http://www.nursingworld.org/EspeciallyForYou/Nurse-
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Researchers), disease and disability are prevented as well as improving symptoms related
to illnesses (http://www.ninr.nih.gov/). The current study provides evidence that this
genetically engineered mouse model of a human disease shows many of the same traits
found in humans with similar conditions. Through this study, we have now provided
support for strategies to initiate treatment of disease as well as address complaints found
in humans. While the seizure phenotype of GEFS+ has been discussed in the literature,
the impact of stress within this condition, as well as the behavioral phenotypes, has
largely remained unexplored. Nurses will be able to use information gained from this
study to focus on specific behavioral assessments in children with this genetic disorder.
ADHD consists of the impairment of attention as well as increased locomotor activity
and is associated with multiple problems such as poorer quality of life (Brunklaus et al.,
2011) and school performance (Diamantopoulou et al., 2007) as well as increased drug
addiction (Falck et al., 2008) and criminal behavior (Langley et al., 2010). Thorough
behavioral assessment may lead to treatment of this symptom thus improving quality of
life (Cannon et al., 2009; Wehmeier et al., 2007). Additionally, acute stress management
appears to be important in those with GEFS+ as it is in other epilepsy conditions
(http://www.bcepilepsy.com/files/Information_Sheets/Stress_Management.pdf;
http://www.epilepsy.com/epilepsy/provoke_stress). Because experiencing stressors is
such a common occurrence in our current society, identifying the effects of stress on
behavior helps add to the body of knowledge regarding manifestations of stress,
specifically in those with GEFS+. Nurses can provide education regarding recognition of
stressful events as well as stress management techniques such as relaxation, distraction or
meditation (Varvogli & Darviri, 2011).
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This study also adds to the body of literature regarding the role of genetics in
human conditions. Integrating genetics into nursing practice allows the nurse to
incorporate a more wholistic approach to patient care and become a full partner in
collaboration with other healthcare providers that are using genetics as part of everyday
practice (Seal, 2011). Nurses use knowledge of genetics when conducting a thorough
medical and multi-generational family history which can help identify patients at risk for
neurological disorders or those with neurological injury. Early interventions and
preventative measures are key to reducing and relieving disease morbidity. Once needs
or risks are identified, it is the nurse’s responsibility to educate patients on their
modifiable risk factors.
While advanced-practice nurses can initiate pharmacological treatments and
nurses administer these treatments in healthcare settings, many non-pharmacological
therapies can be effective with a wide variety of disorders and symptoms. However it is
crucial to make knowledgeable recommendations of complimentary therapies based on
scientific research. Although omega 3 PUFA’s are effective in mitigating some cardiac
dysfunction (Mozaffarian & Wu, 2011), their impact on neurological disorders and
dysfunction is still being investigated. Understanding how these fatty acids can improve
neuronal cell signaling will guide nurses in educating patients on the potential mechanism
of action of n-3 PUFA’s that can benefit patients with epilepsy and co-morbid
neurological disorders.
Nursing research is also needed in the area of omega 3 PUFA’s and neurological
disorders. Understanding how the brain is impacted by essential fatty acids is crucial in
directing appropriate treatment but can also help in prevention of disorders. Sometimes
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healthcare providers focus on treating symptoms when prevention could have occurred.
Nurses should be proactive with their patients in promoting and maintaining health.
Research helps guide our knowledge so that we can thoroughly assess, treat and educate
patients.
Strengths and Weaknesses of Study
The main strength of this study is that the animal model recapitulates the human
condition of GEFS+. The animals were generated in order to have the human genetic
mutation of R1648H on the Scn1a gene. This helps to ensure that data collected from
these animals closely resemble outcomes in humans. Some seizure or behavioral
characteristics cannot be experimentally examined in humans; therefore, this animal
model is ideal for examining seizure and behavioral phenotypes. The strengths of this
study also include maintaining control of the environment and experimental design.
Using an animal model of a human condition allows the researcher to focus on the main
variable (in this case the R1648H missense mutation) with otherwise very little
heterogeneity between subjects. Additionally, all experiments are conducted with the
same age of animal and during the same time of day to remove circadian influences.
Confounding environmental factors play only a minute role in laboratory research. This
means that while every effort is made to maintain environmental control (noise, odors,
and stressors) and use the same experimental procedures with every animal, the
researcher will never be able to eliminate all possible sources of confounders.
Nevertheless, laboratory research provides a good source of control over extraneous
variables. Next, internal consistency was maintained by using the same researcher to
conduct the experiments as well as recording and analyzing the data. This means that
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interpretation of data (i.e., partial seizure vs. a myoclonic jerk, or struggling vs. floating)
was consistent throughout the study. Inter-rater reliability was ascertained by having
another researcher code some of the data and compare with primary researcher. Another
strength is that, when appropriate, animals were randomly assigned to experimental
groups and the primary researcher was blinded to genotype in all experiments except for
the omega 3 PUFA trial in which the primary researcher was required to know genotype
to appropriately assign animals to experimental groups (once genotype was determined,
the animals were still randomly assigned).
Understanding the neurological pathways that are impacted in those with SCN1A
mutations helped to guide the use of the pharmacological as well as non-pharmacological
agents in this study. For example, picrotoxin is a GABAA receptor antagonist (Bast,
Zhang, & Feldon, 2001). Because SCN1A mutations are known to highly impact
GABAergic interneurons (Martin et al., 2010), using this proconvulsant specifically
targeted those pathways. Additionally, DHA is known to impact cell signaling and is
reported to improve [3H]-muscimol (analogous to GABA) binding to GABAA receptors
(Sogaard et al., 2006) which provided rationale for use in this study.
To our knowledge, this is the first study to examine the effects of acute stress on
seizure activity as well as behavioral characteristics in an animal model resembling the
human condition of GEFS+. Additionally, no studies have examined the impact of DHA
on hyperactivity in these animals. When studying behavioral characteristics, especially
using animal models, it is important to replicate results using various experimental
paradigms. This study found hyperactive locomotor behavior within two paradigms
which provides clear and consistent evidence of this abnormal behavior.
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The weaknesses of this study are also important to discuss. While adequate
power was obtained in many of the dependent variables, some of the data analysis
revealed inadequate power which is important to determine significant differences. In
animal research it is crucial to use as few subjects as possible to promote conservation of
animals; however it is just as important to utilize enough animals to maintain adequate
power so that results can be interpreted correctly. Future research will include a few
more animals to obtain power of at least 0.8 in paradigms in which adequate power was
not attained. Another weakness of the study was in the experimental design of the social
interaction test. There are three phases in this paradigm. In the first phase, the animal is
placed in the center of the empty social interaction box. In phase two, a conspecific
‘stranger’ mouse is placed in one of the corners, and in phase three, another conspecific
‘stranger’ mouse is placed in the other corner. For this study, the test mouse was not
removed and replaced in the center of the box during the beginning of phases two or
three. Placing the mouse in the center of the box during the beginning all three phases
would have ensured consistency of the starting point of the test mouse when each
stranger mouse was introduced.
A third weakness of the study was in regard to the dependent variable of anxiety.
In the novel cage experiment, the animals were examined for exploration behavior (i.e.,
grooming, burrowing, and rearing). Because these animals display a clear and consistent
behavior of increased locomotor activity, it is difficult to interpret the data from the novel
cage. If the baseline locomotor behavior of the RH mutants is ‘hyperactive’, then other
measures of movement such as burrowing and rearing may be confounded by the
increased locomotion.
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Recommendations for Future Research
Future recommendations of the study include additions or alterations to the
experimental design. First, another agent to induce epileptogenesis should be used.
Although picrotoxin is a GABAA antagonist, the effects of this drug was not clear and
consistent between RH mutants and their WT littermates. Flurothyl has been used in
animal models of epilepsy, specifically with animals with sodium channel mutations
(Martin et al., 2007; Martin et al., 2010), to examine seizure latencies. Flurothyl also acts
on GABAergic interneurons and would be appropriate to use with this animal model of
GEFS+.
The weaknesses of the social interaction test were discussed earlier; therefore this
experiment should be repeated to make sure the test animal is removed and replaced in
the center of the box at the beginning of each phase when the new stranger mouse is
introduced. Other changes in the experimental paradigm include adding more animals to
the open field experiment to ensure adequate power of at least 0.8. Additionally, a test
that excludes the assessment of locomotor activity should be used to examine potential
anxiety-like behavior. The startle test employs a device that holds the mouse in a small
tube and measures the magnitude of response to an auditory stimulus. This measurement
of anxiety-like behavior does not employ any locomotion; therefore the startle test may
be a good experiment for these animals that have a baseline of increased locomotor
activity.
Grooming activity appears to be a more complex variable than simply assessing
frequency and duration of this behavior. It is suggested that examining the
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microstructure of grooming could be a better indicator of certain behaviors (Kalueff,
Aldridge, LaPorte, Murphy, & Tuohimaa, 2007; Smolinsky, Bergner, LaPorte, &
Kalueff, 2010). Microstructure includes aspects of method of grooming and partial
versus complete grooming. Future experiments could include a more comprehensive
examination of the microstructure of grooming.
The experimental paradigm for specific aim three consisted of two weeks of SQ
DHA injections. Human studies employ a longer time period of consumption of the n-3
PUFA’s (Richardson & Puri, 2002; Sinn & Bryan, 2007; Voigt et al., 2001) although it is
difficult to correlate treatment time in humans compared to treatment time in animals. It
could be that the body needs a longer time period for accretion of DHA into the lipid
bilayer of neuronal cell membranes. Future experiments will use longer duration of n-3
PUFA’s as well as different doses to assess the optimal concentration. The concentration
of 100mg/kg used in this study was thought to reduce the potential side effect of local
irritation at the injection site. It will also be important for future studies to include oral
consumption of PUFA’s rather than SQ injections. Additionally, studies have reported
that prenatal use of n-3 PUFA’s through weaning confers a degree of neuroprotection
against certain insults to the offspring (Zhang et al., 2010). Future studies will examine
the effects of prenatal consumption of DHA (and/or other n-3 PUFA’s) on hyperactive
locomotor behavior in offspring of mice with the RH mutation.
It would also be important to examine the effectiveness of a GABAA agonist in
the treatment of hyperactivity in this model of GEFS+. Muscimol is a GABAA receptor
agonist that has been used in multiple studies to examine the effects of various substances
on GABAA (Del Arco et al., 2011; Pouget, Wattiez, Rivaud-Pchoux, & Gaymard, 2009;
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Sogaard et al., 2006). While there are many other GABAA agonists, Muscimol appears to
be a common agent in animal research. Using a GABAA agonist may help to elucidate
the neuronal pathway responsible for hyperactivity in the RH mutant animals.
It is important to assess how the supplementation of n-3 PUFA’s (whether it is
given orally or by injection) affect serum and brain levels of fatty acids. Human studies
have noted lower levels of fatty acids in the brain in children with ADHD (Colter, Cutler,
& Meckling, 2008), and animal studies using n-3 deficient diets have reported lower
brain levels as well as increased locomotor activity (Lavialle et al., 2008; Levant, Radel,
& Carlson, 2004). Correlating behavior with brain fatty acid levels would be beneficial
in possibly linking increased levels with improved behavior.
We may be able to broaden the results from this study beyond GEFS+ in that
SCN1A contributes to deficits seen in other disorders. Screening for genetic variants in
SCN1A in a population of children with ADHD would also provide further evidence of
the role of this gene in hyperactive behavior.
Conclusion
In conclusion, perhaps for the first time, findings from this study implicate that
stress worsens the seizure phenotype in animals with Scn1a mutation recapitulating
GEFS+. To our knowledge, this study is also the first to report hyperactive locomotor
behavior in an animal model of GEFS+. Further research is needed to replicate findings
of the effects of acute stress in animal models of GEFS+ as well as examining stress in
humans with GEFS+. Additionally, more research is needed regarding the impact of
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omega 3 PUFA’s on neurological sequelae in this animal model and eventually in the
human population.
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APPENDIX A
PICROTOXIN CODING FORM
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Mouse #________________
Latency to Freezing/Staring (≥ 10 sec)___________
0.5) Abnormal Behavior? _____________________
1) Latency to 1st Myoclonic Jerk__________
Total Number of Jerks_________
Time Coded for MJ:
Total Time Coded ___________
Minus Time Seizing__________
Minus Latency to MJ_________
Time Coded for MJ__________
2) Latency to 1st Focal Seizure___________
3) Latency to fully developed bilateral forelimb clonus

____________

3.5) Latency to forelimb clonus with tonic component and twist of the body
____________
4) Latency to GCS with no tonic component _____________
4.5) Latency to GTCS w/ FLE________________
5) Latency to GTCS w/ FLE & HLE____________
5.5) Long-lasting clonus? (yes/no)
6) Death? (yes/no)__________________________
Highest Level on Scale__________
Presence of Grooming at the end? (yes/no)
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APPENDIX B
PICROTOXIN OBSERVATION FORM
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Date:
Mouse #:

Myoclonic Jerk
(Starting Time)

Partial (P) or
Generalized (G)
Tonic Seizure

GTCS
(with bouncing)

Hindlimb
Extension

Status
Epilepticus (>15
min)
Death
Other/Notes:
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APPENDIX C
BEHAVIOR GRID
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Date:
Behavior
Grooming
Duration

Grooming
Frequency

Scratching

Rearing

StretchAttend

Fecal Boli
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APPENDIX D
GENOTYPING
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2 bars equals RH mutant
1 bar equals WT
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APPENDIX E
GSU IACUC APPROVAL FORM
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APPENDIX F
GSU IACUC RENEWAL FORM
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